[
  {
    "question": "A junior orthopaedic surgery resident is completing a carpal tunnel repair with the department chairman as the attending physician. During the case, the resident inadvertently cuts a flexor tendon. The tendon is repaired without complication. The attending tells the resident that the patient will do fine, and there is no need to report this minor complication that will not harm the patient, as he does not want to make the patient worry unnecessarily. He tells the resident to leave this complication out of the operative report. Which of the following is the correct next action for the resident to take?",
    "answer": "To address this scenario, we must apply core ethical principles (transparency, patient autonomy, integrity of medical records) and professional obligations:\n\n\n### Key Ethical & Legal Considerations  \n1. **Patient Autonomy & Informed Consent**: Patients have the right to full disclosure of all events during their care—including unintended complications (even if repaired and not expected to cause harm). This respects their autonomy to understand their treatment journey.  \n2. **Integrity of Medical Records**: The operative report is a legal and clinical document that must be accurate and complete. Omitting a complication (even minor) constitutes falsification, violating ethical standards and legal requirements.  \n3. **Professional Advocacy**: Residents have a duty to advocate for patients, even if this requires addressing disagreements with attendings in a respectful, constructive manner.  \n\n\n### Correct Next Action  \nThe resident’s immediate next step should be to **engage in a respectful conversation with the attending physician** to clarify the ethical and legal imperatives of:  \n- Documenting the flexor tendon injury and repair in the operative report.  \n- Disclosing the incident to the patient (in a compassionate way, emphasizing that the tendon was repaired and no harm is expected).  \n\nThis approach prioritizes resolving the issue collaboratively first, as the attending may not have fully considered the ethical or legal ramifications of omitting the event. If the attending remains unresponsive, the resident should escalate the concern to a higher authority (e.g., ethics committee, program director) to ensure patient rights are protected.\n\n\n**Answer**: The resident should respectfully discuss with the attending the need to document the complication in the operative report and disclose the incident to the patient. (Note: If this were a multiple-choice question, the option reflecting this collaborative, patient-centered communication would be the correct choice.)",
    "expected_answer": "Tell the attending that he cannot fail to disclose this mistake",
    "time": 28.183752059936523,
    "answer_length": 1997
  },
  {
    "question": "A 67-year-old man with transitional cell carcinoma of the bladder comes to the physician because of a 2-day history of ringing sensation in his ear. He received this first course of neoadjuvant chemotherapy 1 week ago. Pure tone audiometry shows a sensorineural hearing loss of 45 dB. The expected beneficial effect of the drug that caused this patient's symptoms is most likely due to which of the following actions?",
    "answer": "To answer this question, we first identify the drug causing the patient’s symptoms and then its mechanism of action:\n\n\n### Step 1: Identify the causative drug  \nThe patient has transitional cell carcinoma (TCC) of the bladder, recent neoadjuvant chemotherapy, and **sensorineural hearing loss + tinnitus**—classic ototoxicity linked to **cisplatin** (a platinum-based chemotherapeutic agent widely used for TCC).\n\n\n### Step 2: Mechanism of cisplatin’s anticancer effect  \nCisplatin exerts its beneficial (anticancer) effect by **forming covalent cross-links between DNA strands** (intrastrand and interstrand cross-links). These cross-links disrupt DNA replication and transcription, leading to cell cycle arrest and apoptosis of cancer cells.\n\n\n**Answer:** Cross-linking of DNA strands.\n\n\n(Note: If this were a multiple-choice question, the correct option would align with DNA cross-linking as the mechanism of cisplatin’s anticancer action.)",
    "expected_answer": "Cross-linking of DNA",
    "time": 19.273006916046143,
    "answer_length": 943
  },
  {
    "question": "Two weeks after undergoing an emergency cardiac catherization with stenting for unstable angina pectoris, a 61-year-old man has decreased urinary output and malaise. He has type 2 diabetes mellitus and osteoarthritis of the hips. Prior to admission, his medications were insulin and naproxen. He was also started on aspirin, clopidogrel, and metoprolol after the coronary intervention. His temperature is 38°C (100.4°F), pulse is 93/min, and blood pressure is 125/85 mm Hg. Examination shows mottled, reticulated purplish discoloration of the feet. Laboratory studies show:\nHemoglobin count 14 g/dL\nLeukocyte count 16,400/mm3\nSegmented neutrophils 56%\nEosinophils 11%\nLymphocytes 31%\nMonocytes 2%\nPlatelet count 260,000/mm3\nErythrocyte sedimentation rate 68 mm/h\nSerum\nUrea nitrogen 25 mg/dL\nCreatinine 4.2 mg/dL\nRenal biopsy shows intravascular spindle-shaped vacuoles. Which of the following is the most likely cause of this patient's symptoms?\"",
    "answer": "To determine the most likely cause of the patient’s symptoms, we analyze the key clinical and laboratory findings alongside the renal biopsy result:\n\n\n### **Key Clinical Clues**  \n- **Temporal association**: Symptoms (decreased urine output, malaise, fever) develop **2 weeks after cardiac catheterization/stenting** (an invasive vascular procedure).  \n- **Skin findings**: Mottled, reticulated purplish discoloration of the feet (livedo reticularis), a classic sign of vascular occlusion.  \n- **Laboratory abnormalities**:  \n  - Eosinophilia (11% vs normal 1-4%), elevated ESR (68 mm/h), fever (38°C).  \n  - Acute renal dysfunction (creatinine 4.2 mg/dL, BUN 25 mg/dL).  \n- **Renal biopsy**: Intravascular spindle-shaped vacuoles (cholesterol crystals dissolve in fixative, leaving these vacuoles).  \n\n\n### **Diagnosis**  \nThese findings are pathognomonic for **cholesterol embolism syndrome (CES)**.  \n\nCES occurs when cholesterol plaques (from atherosclerotic vessels like the aorta) are dislodged during invasive vascular procedures (e.g., catheterization). Emboli travel to organs (kidneys, skin, etc.), causing:  \n- Renal dysfunction (from renal artery/arteriole occlusion).  \n- Skin changes (livedo reticularis, digital ischemia).  \n- Systemic inflammation (fever, eosinophilia, elevated ESR).  \n- Renal biopsy: Spindle-shaped vacuoles in intravascular spaces (residual of dissolved cholesterol crystals).  \n\n\n### **Other Ruling Out**  \n- **Contrast-induced nephropathy**: Occurs within 48-72h of contrast exposure (not 2 weeks later) and lacks eosinophilia/livedo reticularis.  \n- **Drug-induced interstitial nephritis**: Causes interstitial inflammation (not intravascular vacuoles) and does not explain the vascular skin findings.  \n\n\n**Answer: Cholesterol embolism syndrome (secondary to cardiac catheterization)**\n\n\n\\boxed{Cholesterol embolism syndrome}",
    "expected_answer": "Cholesterol embolization",
    "time": 29.679510831832886,
    "answer_length": 1865
  },
  {
    "question": "A 39-year-old woman is brought to the emergency department because of fevers, chills, and left lower quadrant pain. Her temperature is 39.1°C (102.3°F), pulse is 126/min, respirations are 28/min, and blood pressure is 80/50 mm Hg. There is blood oozing around the site of a peripheral intravenous line. Pelvic examination shows mucopurulent discharge from the cervical os and left adnexal tenderness. Laboratory studies show:\nPlatelet count 14,200/mm3\nFibrinogen 83 mg/mL (N = 200–430 mg/dL)\nD-dimer 965 ng/mL (N < 500 ng/mL)\nWhen phenol is applied to a sample of the patient's blood at 90°C, a phosphorylated N-acetylglucosamine dimer with 6 fatty acids attached to a polysaccharide side chain is identified. A blood culture is most likely to show which of the following?\"",
    "answer": "To solve this question, we analyze the clinical presentation, lab findings, and key molecular clue step-by-step:\n\n\n### **Step 1: Clinical & Lab Context**  \nThe patient presents with:  \n- **Pelvic infection**: Mucopurulent cervical discharge, left adnexal tenderness, left lower quadrant pain (consistent with pelvic inflammatory disease, PID).  \n- **Septic shock**: Fever, tachycardia (126/min), hypotension (80/50 mmHg), tachypnea (28/min).  \n- **Disseminated Intravascular Coagulation (DIC)**: Low platelets (14k/mm³), low fibrinogen (83 mg/dL), high D-dimer (965 ng/mL).  \n\n\n### **Step 2: Molecular Clue**  \nThe molecule identified (phosphorylated N-acetylglucosamine dimer with 6 fatty acids attached to a polysaccharide side chain) is **lipid A**, the toxic component of **lipopolysaccharide (LPS)**. LPS is unique to the outer membrane of **Gram-negative bacteria**.  \n\n\n### **Step 3: Pathogen Association**  \nPID is most commonly caused by Gram-negative bacteria like **Neisseria gonorrhoeae** (a Gram-negative diplococcus). Disseminated gonococcal infection can lead to septic shock and DIC, consistent with the patient’s presentation.  \n\n\n**Answer: Neisseria gonorrhoeae** (assuming this is among the options, as it is the classic Gram-negative pathogen for PID with DIC/sepsis).  \n\n(Note: If options were provided, this would be the correct choice based on the clinical and molecular evidence.)\n\n\n\\boxed{Neisseria gonorrhoeae}",
    "expected_answer": "Lactose-fermenting, gram-negative rods forming pink colonies on MacConkey agar",
    "time": 31.373847007751465,
    "answer_length": 1436
  },
  {
    "question": "A 35-year-old man comes to the physician because of itchy, watery eyes for the past week. He has also been sneezing multiple times a day during this period. He had a similar episode 1 year ago around springtime. He has iron deficiency anemia and ankylosing spondylitis. Current medications include ferrous sulfate, artificial tear drops, and indomethacin. He works as an elementary school teacher. His vital signs are within normal limits. Visual acuity is 20/20 without correction. Physical examination shows bilateral conjunctival injection with watery discharge. The pupils are 3 mm, equal, and reactive to light. Examination of the anterior chamber of the eye is unremarkable. Which of the following is the most appropriate treatment?",
    "answer": "To determine the most appropriate treatment for this patient, we first analyze his clinical presentation:  \n\n### Key Clinical Features  \n- **Symptoms**: Itchy/watery eyes (allergic conjunctivitis) + frequent sneezing (seasonal allergic rhinitis)  \n- **Recurrence**: Similar episode last spring (consistent with seasonal allergies)  \n- **Current meds**: Artificial tears (symptomatic relief only), ferrous sulfate (iron deficiency anemia), indomethacin (ankylosing spondylitis)  \n- **No contraindications** to common allergy treatments  \n\n### Rationale for Treatment  \nThe patient needs a therapy that addresses both eye and nose symptoms (since artificial tears do not target the underlying allergic reaction).  \n\n- **Oral second-generation antihistamines** (e.g., loratadine, cetirizine) are first-line:  \n  - Systemic effect covers both conjunctivitis and rhinitis.  \n  - Non-sedating (critical for his role as an elementary school teacher, requiring alertness).  \n  - No interactions with his current medications (ferrous sulfate, indomethacin) or medical conditions (ankylosing spondylitis, iron deficiency anemia).  \n\nOther options (e.g., topical eye antihistamines, intranasal steroids) only address one symptom cluster, making them less optimal.  \n\n**Answer**: Oral second-generation antihistamine (e.g., loratadine).  \n\n(Note: If specific drug names were provided as options, the correct choice would be a non-sedating oral antihistamine.)  \n\n\\boxed{Loratadine} (or any equivalent second-generation oral antihistamine like cetirizine)  \n\n(Assuming standard USMLE-style options, this is the most appropriate answer.)",
    "expected_answer": "Ketotifen eye drops",
    "time": 37.56759786605835,
    "answer_length": 1623
  },
  {
    "question": "A 39-year-old man presents to the emergency department because of progressively worsening chest pain and nausea that started at a local bar 30 minutes prior. The pain radiates to the epigastric area. He has a 5-year history of untreated hypertension. He has smoked 1 pack of cigarettes daily for the past 5 years and started abusing cocaine 2 weeks before his emergency room visit. The patient is diaphoretic and in marked distress. What should be the first step in management?",
    "answer": "To determine the first step in management for this patient, we analyze their presentation and key clinical clues:\n\n\n### **Key Clinical Context**  \nThe patient is a 39-year-old man with:  \n- Progressive chest pain (radiating to epigastrium) + nausea, diaphoresis, marked distress (classic for acute coronary syndrome [ACS]).  \n- **Cocaine use (2 weeks prior, onset 30 mins before presentation)**: A potent stimulant causing vasoconstriction, increased heart rate/BP, and high risk of myocardial ischemia/infarction in young adults.  \n\n\n### **First Step in Management**  \nFor any patient with chest pain suspicious for cardiac origin (especially with cocaine use), the **immediate priority** is to evaluate for ST-elevation myocardial infarction (STEMI) or ischemia. This requires:  \n\n**Obtaining a 12-lead ECG within 10 minutes of arrival.**  \n\nAn ECG is critical to:  \n- Rule out STEMI (which demands urgent reperfusion therapy).  \n- Identify ischemia (non-STEMI/unstable angina) to guide subsequent management.  \n\n\n### **Why Other Options Are Not First**  \n- **ABCs**: While foundational, the patient’s presentation (no airway/breathing compromise mentioned) means ECG is the next urgent step to address the likely cardiac cause.  \n- **Aspirin**: Indicated for ACS but depends on ECG findings (and is not the *first* step).  \n- **Nitroglycerin**: May relieve pain but is secondary to ECG evaluation.  \n\n\n**Answer: Obtain a 12-lead ECG immediately.**",
    "expected_answer": "Reassurance and continuous monitoring",
    "time": 46.07197904586792,
    "answer_length": 1450
  },
  {
    "question": "A 68-year-old male comes to the physician for evaluation of right flank pain. He has a history of diabetes and peripheral artery disease. His blood pressure is 160/90 mm Hg. Physical examination shows abdominal tenderness and right flank tenderness. An ultrasound shows dilation of the right ureter and renal pelvis. Which of the following is the most likely underlying cause of this patient's condition?",
    "answer": "To determine the most likely underlying cause of the patient’s condition, let’s analyze the key findings and context:\n\n\n### **Key Clinical Features**  \n- **Symptoms**: Right flank pain, abdominal tenderness.  \n- **Imaging**: Dilation of the right ureter and renal pelvis (**hydronephrosis**), indicating **urinary tract obstruction**.  \n- **Patient Profile**: 68-year-old male with diabetes, peripheral artery disease, and hypertension.  \n\n\n### **Analysis of Potential Causes**  \nHydronephrosis arises from obstruction of urine flow. For unilateral hydronephrosis (right-sided here) in an older male, the most common causes are:  \n1. **Ureteral calculus (nephrolithiasis)**: Classic cause of acute flank pain and hydronephrosis. While the patient has no explicit risk factors for stones (e.g., hypercalcemia), it remains the most prevalent cause of acute unilateral ureteral obstruction in adults.  \n2. **BPH**: Typically causes bladder outlet obstruction (bilateral hydronephrosis if severe), not unilateral.  \n3. **Ureteral stricture**: Less likely without prior surgery or infection.  \n4. **Tumor**: Possible but less common than stones in acute presentations.  \n\n\n### **Conclusion**  \nThe most likely underlying cause is **nephrolithiasis (kidney stone)** leading to ureteral obstruction and hydronephrosis.\n\n\n**Answer: Nephrolithiasis (or Ureteral calculus)**  \n(Note: Depending on standard terminology, the exact phrase may vary, but the core cause is a urinary stone.)",
    "expected_answer": "Common iliac artery aneurysm",
    "time": 31.791554927825928,
    "answer_length": 1475
  },
  {
    "question": "A 65-year-old man is brought to the emergency department 30 minutes after the onset of acute chest pain. He has hypertension and asthma. Current medications include atorvastatin, lisinopril, and an albuterol inhaler. He appears pale and diaphoretic. His pulse is 114/min and blood pressure is 130/88 mm Hg. An ECG shows ST-segment depressions in leads II, III, and aVF. Laboratory studies show an increased serum troponin T concentration. The patient is treated for acute coronary syndrome and undergoes percutaneous transluminal coronary angioplasty. At the time of discharge, echocardiography shows a left ventricular ejection fraction of 58%. In addition to aspirin, which of the following drugs should be added to this patient's medication regimen?",
    "answer": "To answer this question, we need to apply standard post-acute coronary syndrome (ACS) management guidelines, considering the patient’s comorbidities (hypertension, asthma) and normal left ventricular ejection fraction (58%, within the normal range of 50-70%).\n\n\n### Key Background:  \nPost-ACS care prioritizes reducing recurrent ischemia and mortality. Core interventions include:  \n1. **Dual Antiplatelet Therapy (DAPT):** Aspirin plus a P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) is mandatory for 6-12 months to prevent stent thrombosis and recurrent events.  \n2. **Beta-blockers:** Cardioselective beta-blockers (e.g., metoprolol succinate) are recommended for all ACS patients without contraindications (e.g., severe asthma exacerbations). However, the patient’s asthma is controlled with albuterol, so cardioselective beta-blockers are safe—but DAPT is a higher-priority initial addition to aspirin.  \n3. **ACE inhibitors/statins:** The patient is already on lisinopril (ACE inhibitor) and atorvastatin (statin), so these are not new additions.  \n\n\n### Critical Consideration for Asthma:  \nP2Y12 inhibitors (e.g., clopidogrel) have no contraindications in asthma, making them safe and essential for DAPT.  \n\n\n**Answer:** Clopidogrel (or another P2Y12 inhibitor, but clopidogrel is the most common first-line choice here).\n\n\n\\boxed{Clopidogrel}",
    "expected_answer": "Clopidogrel",
    "time": 50.897154092788696,
    "answer_length": 1358
  },
  {
    "question": "A 37-year-old-woman presents to her primary care physician requesting a new form of birth control. She has been utilizing oral contraceptive pills (OCPs) for the past 8 years, but asks to switch to an intrauterine device (IUD). Her vital signs are: blood pressure 118/78 mm Hg, pulse 73/min and respiratory rate 16/min. She is afebrile. Physical examination is within normal limits. Which of the following past medical history statements would make copper IUD placement contraindicated in this patient?",
    "answer": "To determine the contraindication for copper IUD placement, we rely on established guidelines (e.g., CDC Medical Eligibility Criteria) and key clinical knowledge about copper IUDs:\n\n\n### Key Background:  \nCopper IUDs release copper ions into the uterine cavity. Their absolute contraindications include conditions where extra copper exposure is harmful or the device cannot be safely placed/retention is compromised.\n\n\n### Critical Contraindication:  \n**Wilson’s disease** is an absolute contraindication for copper IUDs. This genetic disorder impairs copper metabolism (defect in ATP7B gene), leading to toxic accumulation of copper in the liver, brain, and other organs. Adding extra copper via the IUD exacerbates this toxicity, posing an unacceptable risk.\n\n\n### Elimination of Other Common Options:  \n- **Endometriosis**: Not contraindicated (copper IUDs are hormone-free and safe for endometriosis patients).  \n- **Gestational diabetes**: Past gestational diabetes does not affect copper IUD eligibility.  \n- **Migraine with aura**: Contraindication for estrogen-containing contraceptives (e.g., OCPs), but not for hormone-free copper IUDs.  \n- **Breast cancer**: Copper IUDs are hormone-free and safe for survivors of non-active breast cancer.  \n\n\n**Answer: History of Wilson’s disease** (assuming this was an option in the original question).  \n\nIf forced to state the answer without explicit options (based on standard exam questions), the most likely correct response is:  \n\n**Wilson's disease**\n\n\n\\boxed{Wilson's disease}",
    "expected_answer": "Active or recurrent pelvic inflammatory disease (PID)",
    "time": 35.569055795669556,
    "answer_length": 1532
  },
  {
    "question": "A 23-year-old woman comes to the physician because she is embarrassed about the appearance of her nails. She has no history of serious illness and takes no medications. She appears well. A photograph of the nails is shown. Which of the following additional findings is most likely in this patient?",
    "answer": "To answer this question, the necessary information—the photograph of the patient’s nails—was not provided in the input. Without observing the specific nail appearance (e.g., spoon-shaped nails, clubbing, white spots, etc.), it is impossible to determine the most likely additional finding in this patient. Please provide the photograph or a description of the nail features to allow for an accurate analysis.",
    "expected_answer": "Silvery plaques on extensor surfaces",
    "time": 11.815891981124878,
    "answer_length": 408
  },
  {
    "question": "A 24-year-old G2P1 woman at 39 weeks’ gestation presents to the emergency department complaining of painful contractions occurring every 10 minutes for the past 2 hours, consistent with latent labor. She says she has not experienced vaginal discharge, bleeding, or fluid leakage, and is currently taking no medications. On physical examination, her blood pressure is 110/70 mm Hg, heart rate is 86/min, and temperature is 37.6°C (99.7°F). She has had little prenatal care and uses condoms inconsistently. Her sexually transmitted infections status is unknown. As part of the patient’s workup, she undergoes a series of rapid screening tests that result in the administration of zidovudine during delivery. The infant is also given zidovudine to reduce the risk of transmission. A confirmatory test is then performed in the mother to confirm the diagnosis of HIV. Which of the following is most true about the confirmatory test?",
    "answer": "To answer this question, we need to recall the standard **HIV diagnostic testing algorithm**, focusing on the confirmatory test step:\n\n\n### Key Background on HIV Testing  \nHIV diagnosis typically follows a two-step process:  \n1. **Screening test**: Rapid tests or fourth-generation antigen/antibody assays (detect p24 antigen + antibodies to HIV-1/HIV-2).  \n2. **Confirmatory test**: Required to validate a positive screening result. The gold-standard confirmatory test historically (and still widely referenced) is the **Western blot**, which detects **antibodies to specific HIV proteins** (e.g., gp120, gp41 for HIV-1; gp36 for HIV-2).  \n\nOther confirmatory tests (e.g., immunofluorescence assay [IFA]) also target specific HIV antibodies, but the Western blot is the most commonly cited example.\n\n\n### Elimination of Distractors (Typical Options)  \n- **Detects HIV RNA**: This is a viral load test, not confirmatory (used for monitoring disease progression or treatment response).  \n- **Detects p24 antigen**: Part of screening (fourth-gen assays), not confirmatory.  \n- **Is a rapid test**: Rapid tests are screening tools, not confirmatory.  \n- **Measures viral load**: Quantitative, not confirmatory.  \n\n\n**Answer**: The confirmatory test detects antibodies to specific HIV proteins.  \n\n(Note: If options were provided, the correct choice would align with this statement.)\n\n\n**Final Answer**  \nThe confirmatory test detects antibodies to specific HIV proteins.  \n\n(If formatted as a multiple-choice option, select the one stating this.)  \n\n\\boxed{It detects antibodies to specific HIV proteins}",
    "expected_answer": "It is an HIV-1/HIV2 antibody differentiation immunoassay",
    "time": 31.664078950881958,
    "answer_length": 1601
  },
  {
    "question": "A 72-year-old man comes to the physician because of a 2-month history of fatigue and worsening abdominal pain. During this period, he also has excessive night sweats and shortness of breath on exertion. Over the past 3 months, he has had a 5.6-kg (12-lb) weight loss. He had a myocardial infarction 3 years ago. He has hypertension, diabetes mellitus, and chronic bronchitis. His medications include insulin, aspirin, lisinopril, and an albuterol inhaler. He has smoked half a pack of cigarettes for the past 45 years. Vital signs are within normal limits. The spleen is palpated 6 cm below the left costal margin. Laboratory studies show:\nHemoglobin 6.4 g/dL\nMean corpuscular volume 85 μm3\nLeukocyte count 5,200/mm3\nPlatelet count 96,000/mm3\nA blood smear is shown. Bone marrow aspiration shows extensive fibrosis and a few scattered plasma cells. A JAK 2 assay is positive. Which of the following is the most appropriate next step in management?\"",
    "answer": "To answer this question, we first need to **diagnose the patient’s condition** based on clinical and lab findings, then identify the appropriate next step in management.\n\n\n### Step 1: Diagnosis  \nThe key findings point to **primary myelofibrosis (PMF)**, a myeloproliferative neoplasm (MPN):  \n- **Clinical symptoms**: Fatigue (anemia), abdominal pain (splenomegaly), night sweats/weight loss (B symptoms), dyspnea on exertion.  \n- **Physical exam**: Splenomegaly (spleen 6cm below costal margin, due to extramedullary hematopoiesis).  \n- **Labs**: Normocytic anemia (Hb=6.4g/dL), thrombocytopenia (platelets=96k/mm³), **JAK2 positivity** (common in ~50-60% of PMF cases).  \n- **Bone marrow**: Extensive fibrosis (hallmark of PMF).  \n\n\n### Step 2: Management of PMF  \nFor patients with **intermediate/high-risk PMF** (this patient meets criteria: age>65y, Hb<10g/dL, platelets<100k/mm³ + symptomatic splenomegaly/B symptoms), the **first-line targeted therapy** is a **JAK inhibitor** (e.g., ruxolitinib).  \n\nRuxolitinib (a JAK1/JAK2 inhibitor) addresses both:  \n- Symptomatic splenomegaly (reduces spleen size).  \n- Systemic symptoms (night sweats, weight loss, fatigue).  \n\nSupportive care (e.g., transfusions for anemia) is adjunctive but not the primary next step for this patient’s high-risk, symptomatic disease.\n\n\n### Final Answer  \nThe most appropriate next step is to initiate a JAK inhibitor (e.g., ruxolitinib).  \n\n(Note: If options were provided, the correct choice would likely include \"ruxolitinib\" or \"JAK inhibitor therapy\".)\n\n\n**Answer:** Initiate ruxolitinib (JAK inhibitor therapy).  \n(If formatted as a single line for standard exam-style answers: **Ruxolitinib**)",
    "expected_answer": "Ruxolitinib",
    "time": 50.14837384223938,
    "answer_length": 1684
  },
  {
    "question": "A 20-year-old man comes to the physician because of worsening gait unsteadiness and bilateral hearing loss for 1 month. He has had intermittent tingling sensations on both cheeks over this time period. He has no history of serious medical illness and takes no medications. Audiometry shows bilateral sensorineural hearing loss. Genetic evaluation shows a mutation of a tumor suppressor gene on chromosome 22 that encodes merlin. This patient is at increased risk for which of the following conditions?",
    "answer": "To answer this question, we first identify the patient's key features and their underlying condition:  \n\n### Key Patient Details:  \n- 20-year-old man with bilateral sensorineural hearing loss, gait unsteadiness, cheek tingling.  \n- Genetic mutation: Tumor suppressor gene on chromosome 22 encoding **merlin** (NF2 gene).  \n\n### Diagnosis:  \nThis mutation confirms **Neurofibromatosis Type 2 (NF2)**, a genetic disorder characterized by an increased risk of CNS tumors.  \n\n### Classic Associations of NF2:  \nThe most hallmark and common condition associated with NF2 is **bilateral vestibular schwannomas** (acoustic neuromas), which directly explain the patient’s bilateral hearing loss and gait unsteadiness (vestibular dysfunction). Additionally, NF2 patients are at high risk for other tumors like meningiomas, trigeminal schwannomas (explaining cheek tingling from trigeminal nerve involvement), ependymomas, etc.  \n\n### Likely Answer:  \nGiven the question’s context (and typical exam questions), the most classic and direct answer is **bilateral vestibular schwannomas** (or acoustic neuromas). If other options are considered, **meningioma** is another strong candidate, but the hallmark of NF2 is bilateral vestibular schwannomas.  \n\n**Answer:** Bilateral vestibular schwannomas (acoustic neuromas)  \n\n(Note: If the original question included options, this would align with the most relevant choice.)  \n\n\\boxed{Bilateral vestibular schwannomas}",
    "expected_answer": "Meningioma",
    "time": 43.073368072509766,
    "answer_length": 1451
  },
  {
    "question": "A 47-year-old executive schedules an appointment his physician for a routine medical check-up. He currently has no complaints and claims to be “as fit as a fiddle.” The physical examination findings are unremarkable, except for a mid-systolic murmur heard in the 2nd left intercostal space that radiates to the carotids on auscultation. The physician instructs the patient to stand from a supine position with the stethoscope still placed on his chest. Which of the following changes would occur with this maneuver?",
    "answer": "To answer this question, we first identify the nature of the murmur and then analyze the hemodynamic effects of standing:\n\n\n### Step 1: Identify the murmur  \nThe patient has a **mid-systolic murmur** at the **2nd left intercostal space (aortic area)** radiating to the carotids. This is classic for **aortic stenosis (AS)**, a fixed valvular obstruction of the aortic valve.\n\n\n### Step 2: Hemodynamic effect of standing  \nStanding reduces venous return to the heart due to gravity (blood pools in the legs), leading to a **decrease in left ventricular end-diastolic volume (LVEDV, preload)**.\n\n\n### Step 3: Impact on AS murmur  \nThe intensity of the AS murmur depends on the volume of blood flowing through the stenotic aortic valve during systole. A decrease in preload (standing) reduces stroke volume, so less blood flows across the aortic valve. This **diminishes the murmur intensity**.\n\n\n**Answer:** The murmur decreases in intensity.\n\n\n\\boxed{The murmur decreases in intensity}",
    "expected_answer": "A reduction in diastolic filling time",
    "time": 26.793994188308716,
    "answer_length": 984
  },
  {
    "question": "A microbiologist is studying the emergence of a virulent strain of the virus. After a detailed study of the virus and its life cycle, he proposes a theory: Initially, a host cell is co-infected with 2 viruses from the same virus family. Within the host cell, concomitant production of various genome segments from both viruses occurs. Ultimately, the different genome segments from the viruses are packaged into a unique and novel virus particle. The newly formed virus particle is both stable and viable and is a new strain from the virus family that caused the outbreak of infection. Which of the following viruses is capable of undergoing the above-mentioned process?",
    "answer": "To solve this question, we first identify the key process described: **genetic reassortment**—a phenomenon where two viruses with segmented genomes co-infect a host cell, leading to the packaging of mixed genome segments from both viruses into new, viable particles. This process requires the virus to have a **segmented genome**.\n\n\n### Key Analysis:\nReassortment is characteristic of viruses with segmented genomes. The most well-known example of such a virus (relevant to pathology and outbreaks) is **Influenza A virus** (family Orthomyxoviridae), which has an 8-segmented single-stranded RNA genome. Influenza A frequently undergoes reassortment (e.g., between human, avian, and swine strains) to form new virulent strains that cause pandemics (e.g., 2009 H1N1).\n\n\n### Conclusion:\nThe virus capable of the described process is **Influenza A virus**.\n\n\n**Answer:** Influenza A virus (or simply Influenza virus, given the context).\n\n\n\\boxed{Influenza\\ virus}",
    "expected_answer": "Rotavirus",
    "time": 27.475433111190796,
    "answer_length": 960
  },
  {
    "question": "A 59-year-old overweight woman presents to the urgent care clinic with the complaint of severe abdominal pain for the past 2 hours. She also complains of a dull pain in her back with nausea and vomiting several times. Her pain has no relation with food. Her past medical history is significant for recurrent abdominal pain due to cholelithiasis. Her father died at the age of 60 with some form of abdominal cancer. Her temperature is 37°C (98.6°F), respirations are 15/min, pulse is 67/min, and blood pressure is 122/98 mm Hg. Physical exam is unremarkable. However, a CT scan of the abdomen shows a calcified mass near her gallbladder. Which of the following diagnoses should be excluded first in this patient?",
    "answer": "To determine the diagnosis that should be excluded first, we analyze the patient’s key clinical features and prioritize serious, high-risk conditions aligned with her findings:\n\n\n### Key Clinical Findings  \n- 59-year-old overweight woman with **recurrent cholelithiasis** (gallstones).  \n- Severe abdominal pain (2h), back pain, nausea/vomiting (pain unrelated to food).  \n- CT shows a **calcified mass near the gallbladder**.  \n- Family history of abdominal cancer (father died at 60 from abdominal cancer).  \n\n\n### Critical Association  \nA calcified mass near the gallbladder is highly suggestive of **porcelain gallbladder** (calcification of the gallbladder wall), which is strongly linked to an increased risk of **gallbladder carcinoma** (malignancy). This risk is significant enough that porcelain gallbladder often warrants prophylactic cholecystectomy to prevent cancer.  \n\n\n### Why This Diagnosis Is Prioritized  \nGallbladder carcinoma is a life-threatening condition with poor prognosis if not detected early. Given her age, overweight status (risk factors for gallbladder disease), porcelain gallbladder (calcified mass), and family history of abdominal cancer, excluding gallbladder carcinoma is the highest priority to rule out malignancy before considering benign conditions (e.g., acute cholecystitis, which is less likely here due to normal temperature and unremarkable physical exam).  \n\n\n**Answer: Gallbladder carcinoma**",
    "expected_answer": "Gallbladder cancer",
    "time": 21.146244049072266,
    "answer_length": 1440
  },
  {
    "question": "A 7-year-old boy is brought to his pediatrician’s office for a follow-up visit. He was diagnosed with asthma when he was 3 years old and has since been on treatment for the condition. He is currently on a β-agonist inhaler because of exacerbation of his symptoms. He has observed that his symptoms are more prominent in springtime, especially when the new flowers are blooming. His mother has a backyard garden and whenever he goes out to play there, he experiences chest tightness with associated shortness of breath. He has been advised to take more precaution during this seasonal change and to stay away from pollen. He is also being considered for an experimental therapy, which attenuates the activity of certain mediators which cause his asthmatic attack. The targeted mediator favors the class switching of antibodies. A reduction in this mechanism will eventually reduce the exaggerated response observed during his asthmatic attacks, even when exposed to an allergen. Which of the following mediators is described in this experimental study?",
    "answer": "To solve this question, we need to identify the mediator responsible for antibody class switching (specifically to IgE) in allergic asthma, as described in the experimental therapy.\n\n\n### Key Background  \nAllergic asthma is a type I hypersensitivity reaction driven by **IgE antibodies**. B cells switch from producing IgM to IgE via the action of specific cytokines. The critical cytokine for this class switching is **IL-4**.  \n\n\n### Analysis of the Question  \nThe experimental therapy targets a mediator that \"favors class switching of antibodies.\" Since the boy’s asthma is triggered by allergens (pollen) and involves IgE-mediated mast cell degranulation, the mediator in question must induce B cells to switch to IgE production.  \n\n**IL-4** is produced by Th2 cells and directly promotes B cell class switching to IgE. Reducing IL-4 activity would decrease IgE levels, thereby attenuating the allergic response (asthma attacks) even when exposed to allergens.  \n\n\n**Answer: IL-4** (Interleukin-4)  \n\n\\boxed{IL-4}",
    "expected_answer": "IL-4",
    "time": 17.343247890472412,
    "answer_length": 1018
  },
  {
    "question": "A 3-month-old boy is brought the emergency department by his parents after an episode of cyanosis and muscle hypotonia that resolved after 2 minutes. Diagnostic evaluation fails to discover an exact etiology of the boy's symptoms and the episode is classified as a brief resolved unexplained event (BRUE). The risk profile for BRUE in infants remains largely unknown. The pediatrician who saw the boy in the emergency department is trying to identify risk factors for BRUE. She is aware of several confounders, including age, socioeconomic background, and family history of medical illness. She recruits 75 infants under 1 year of age with BRUE and 75 infants without BRUE of the same age, socioeconomic background, and family history of medical illness. She then compares the two groups with regard to history of feeding problems and history of recent upper respiratory infection. Which of the following methods was conducted to control confounding bias in the study?",
    "answer": "To determine the method used to control confounding bias, we analyze the study design described:\n\n\n### Key Observations from the Scenario  \nThe pediatrician recruited **cases (infants with BRUE)** and **controls (infants without BRUE)** that were **matched on age, socioeconomic background, and family history of medical illness** (the identified confounders). This ensures the two groups have identical or similar distributions of these confounding variables, eliminating their potential to distort the comparison between the groups (e.g., history of feeding problems/recent URI).\n\n\n### Distinction from Other Methods  \n- **Stratification**: Involves analyzing data in subgroups defined by confounders *after* data collection, not during recruitment.  \n- **Randomization**: Applies to experimental studies (e.g., RCTs), not observational case-control studies.  \n- **Statistical adjustment**: Uses regression or other models to control confounders *statistically*, not via recruitment matching.  \n\n\n**Answer: Matching** (specifically, frequency matching, as groups are balanced on confounders rather than 1:1 individual matching, but \"matching\" is the core method here).\n\n\n\\boxed{Matching}",
    "expected_answer": "Matching",
    "time": 19.241765022277832,
    "answer_length": 1189
  },
  {
    "question": "A 29-year-old man presents to the emergency department due to central chest pain over the past 3 days which is constant and unrelated to exertion. The pain is sharp, severe, increases when lying down, and improves with leaning forward. The pain also radiates to his shoulders and neck. The patient has no past medical history. He has smoked 10 cigarettes per day for the past 7 years and occasionally drinks alcohol. He presents with vital signs: blood pressure 110/70 mm Hg, regular radial pulse of 95/min, and temperature 37.3°C (99.1°F). On physical exam, a scratching sound of to-and-from character is audible over the left sternal border at end-expiration with the patient leaning forward. His chest X-ray is normal and ECG is shown in the picture. Which of the following is the optimal therapy for this patient?",
    "answer": "To determine the optimal therapy for this patient, we first need to establish the diagnosis based on clinical findings:\n\n\n### **Step 1: Diagnosis**  \nThe patient presents with:  \n- **Chest pain**: Sharp, constant, worse when lying down, better leaning forward (classic for pericarditis).  \n- **Pericardial friction rub**: A \"scratching to-and-from sound\" over the left sternal border (pathognomonic for pericarditis).  \n- **Mild fever**: Suggests inflammation.  \n- **Normal chest X-ray**: Rules out significant pericardial effusion (though small effusions may be present).  \n\nThe diagnosis is **acute idiopathic pericarditis** (most common cause, often viral origin like Coxsackie virus).\n\n\n### **Step 2: Optimal Therapy**  \nAccording to the European Society of Cardiology (ESC) guidelines for pericardial diseases:  \n- **First-line**: NSAIDs (e.g., ibuprofen, indomethacin) to reduce inflammation and pain, plus **colchicine** to lower recurrence risk.  \n\nColchicine is recommended in combination with NSAIDs for all cases of acute idiopathic pericarditis (dose: 0.5mg twice daily for 3 months in adults <70kg). Corticosteroids are reserved for refractory cases or specific etiologies (e.g., autoimmune disease), not first-line. Antibiotics are unnecessary here (no evidence of bacterial infection).\n\n\n**Answer**: NSAID (e.g., ibuprofen) plus colchicine.  \n\n(Note: If specific drug names are expected, common options are ibuprofen 600-800mg 3x/day and colchicine 0.5mg 2x/day.)\n\n\n**Final Answer**: Combination of nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine. For example, ibuprofen plus colchicine.  \n\n(If the question expects a single choice format, the standard answer is **NSAID + colchicine**.)  \n\nBut since the user might expect a concise answer in line with typical exam responses:  \n\n**Optimal therapy: Ibuprofen (or another NSAID) plus colchicine.**  \n\nOr, if we need to state it clearly:  \n\nThe optimal therapy is a combination of nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine.  \n\\boxed{NSAIDs + colchicine}  \n\n(Adjusting to the expected format—though in real exams, it's usually a drug name pair, but this is the core.)\n\n\n\\boxed{Ibuprofen plus colchicine} (as a specific example)  \n\nAlternatively, if the question allows for the general category:  \n\n\\boxed{NSAIDs and colchicine}\n</think_never_used_51bce0c785ca2f68081bfa7d91973934>\nThe optimal therapy for this patient is a combination of nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine.  \n\n### Key Rationale:  \nThe patient’s clinical presentation (sharp chest pain worse lying down/better leaning forward, pericardial friction rub, mild fever) confirms **acute idiopathic pericarditis** (most common viral origin).  \n\n- **NSAIDs** (e.g., ibuprofen) reduce inflammation and pain.  \n- **Colchicine** lowers the risk of recurrence and is recommended in combination with NSAIDs as first-line therapy per guidelines.  \n\nCorticosteroids are reserved for refractory cases, and antibiotics are unnecessary (no bacterial infection evidence).  \n\n**Answer:** \\boxed{Ibuprofen plus colchicine} (specific example) or \\boxed{NSAIDs and colchicine} (general category).  \n\nFor exam purposes, the standard concise answer is:  \n\\boxed{NSAIDs + colchicine}",
    "expected_answer": "Ibuprofen + colchicine +/- omeprazole",
    "time": 41.99762511253357,
    "answer_length": 3244
  },
  {
    "question": "A 46-year-old man is brought to the emergency department for evaluation of altered mental status. He was found on the floor in front of his apartment. He is somnolent but responsive when aroused. His pulse is 64/min, respiratory rate is 15/min, and blood pressure is 120/75 mm Hg. On physical examination, an alcoholic smell and slurred speech are noted. Neurological exam shows diminished deep tendon reflexes bilaterally and an ataxic gait. His pupils are normal. Blood alcohol concentration is 0.04%. An ECG shows no abnormalities. Which of the following is the most likely cause of this patient's symptoms?",
    "answer": "To determine the most likely cause of the patient’s symptoms, let’s analyze the key findings and rule out other possibilities:\n\n\n### **Key Patient Findings**  \n- 46-year-old man with **alcoholic smell** but **low blood alcohol concentration (BAC = 0.04%)** (too low for acute intoxication).  \n- Symptoms: Somnolence (altered mental status), slurred speech, bilateral diminished deep tendon reflexes, ataxic gait, normal pupils, and normal vital signs (no tachycardia/hypertension, ruling out autonomic hyperactivity).  \n\n\n### **Ruling Out Other Conditions**  \n1. **Acute alcohol intoxication**: BAC of 0.04% is insufficient to cause severe symptoms like somnolence or ataxia (legal impairment typically starts at ~0.08%).  \n2. **Alcohol withdrawal**: Characterized by tremors, anxiety, autonomic hyperactivity (tachycardia, hypertension), or seizures—absent here.  \n3. **Hypoglycemia**: Unlikely (no mention of low glucose, and no sweating/tachycardia).  \n4. **Stroke**: Focal deficits (e.g., one-sided weakness) are absent; no cardioembolic clues (normal ECG).  \n\n\n### **Most Likely Cause: Wernicke Encephalopathy**  \nThis is a complication of **thiamine (B1) deficiency**, common in chronic alcoholics (due to poor nutrition and impaired thiamine absorption). Its classic triad is:  \n- Mental confusion (somnolence here),  \n- Ataxia (unsteady gait),  \n- Ophthalmoplegia (eye movement issues—may not always be present early).  \n\nThe patient’s symptoms (ataxia, altered mental status, slurred speech) align with Wernicke’s, even without ophthalmoplegia (triad symptoms are often incomplete). The alcoholic smell confirms chronic alcohol use, the root cause of thiamine deficiency.  \n\n\n**Answer: Wernicke Encephalopathy** (or Thiamine Deficiency, but Wernicke Encephalopathy is the specific acute presentation).  \n\n(Note: If the question expects a more concise term, \"Wernicke Encephalopathy\" is the standard answer here.)  \n\n\\boxed{Wernicke\\ Encephalopathy}",
    "expected_answer": "Benzodiazepine intoxication\n\"",
    "time": 43.04727792739868,
    "answer_length": 1957
  },
  {
    "question": "A 77-year-old woman presents to the emergency room with the complaints of fever, malaise, and night sweats. She recently observed an enlargement of her axillary lymph nodes, which she examines on a weekly basis. She has a remote history of breast cancer in her 60s that was treated with radiation and chemotherapy. She also reports a history of extensive travel to Africa and a 30-pack-year history of smoking. On physical exam, several axillary lymph nodes are palpable with a large non-tender palpable mass in her right axilla measuring 10 x 8 cm. Fine-needle aspiration demonstrates what the pathologist describes as \"a centroblastic and immunoblastic cell presence, suspicious for non-Hodgkin’s lymphoma (NHL)–diffuse large B cell variant\". Which of the following risk factors is responsible for this patient’s condition?",
    "answer": "To determine the responsible risk factor for the patient’s diffuse large B cell non-Hodgkin’s lymphoma (NHL), we analyze her history and key risk factors for this condition:\n\n\n### Key Patient History & Risk Factor Analysis  \nThe patient has:  \n1. **Remote breast cancer treated with radiation and chemotherapy** (in her 60s).  \n2. Extensive Africa travel, 30-pack-year smoking history.  \n\n\n### Critical Risk Factor for Diffuse Large B Cell NHL  \nPrior **radiation therapy and chemotherapy** (especially alkylating agents or anthracyclines) for a previous malignancy (like breast cancer) is an established risk factor for secondary NHL. These treatments damage DNA, leading to mutations that can trigger lymphoma development years later.  \n\nOther factors (smoking, Africa travel) are not directly linked to diffuse large B cell NHL:  \n- Smoking is associated with some cancers but not as a primary risk for this NHL subtype.  \n- Africa travel (e.g., malaria exposure) is linked to Burkitt’s lymphoma (EBV/malaria-associated) but not diffuse large B cell NHL.  \n\n\n**Answer:** Her past treatment with radiation and chemotherapy for breast cancer.  \n\n\\boxed{Past treatment with radiation and chemotherapy for breast cancer}",
    "expected_answer": "Previous radiation therapy",
    "time": 16.761482000350952,
    "answer_length": 1219
  },
  {
    "question": "A 3-month-old infant is brought to her pediatrician because she coughs and seems to have difficulty breathing while feeding. In addition, she seems to have less energy compared to other babies and appears listless throughout the day. She was born by cesarean section to a G1P1 woman with no prior medical history and had a normal APGAR score at birth. Her parents say that she has never been observed to turn blue. Physical exam reveals a high-pitched holosystolic murmur that is best heard at the lower left sternal border. The most likely cause of this patient's symptoms is associated with which of the following abnormalities?",
    "answer": "To determine the most likely cause of the infant’s symptoms, we analyze the key clinical findings and correlate them with common congenital heart defects:\n\n\n### **Key Clinical Features**  \n- 3-month-old infant with **feeding difficulty (cough/breathing issues while feeding)**, **fatigue/listlessness**, and **no cyanosis**.  \n- Physical exam: **high-pitched holosystolic murmur** best heard at the **lower left sternal border (LLSB)**.  \n\n\n### **Differential Diagnosis of Murmurs**  \n- **Ventricular Septal Defect (VSD)**:  \n  - Classic finding: Holosystolic, harsh murmur at LLSB (due to left-to-right shunting across the ventricular septum).  \n  - Symptoms: Feeding difficulty (increased energy demand from shunting), fatigue (heart overwork), and no cyanosis (acyanotic left-to-right shunt initially).  \n  - This matches all the infant’s symptoms and exam findings.  \n\n- Other possibilities are less likely:  \n  - **Atrial Septal Defect (ASD)**: Systolic ejection murmur (not holosystolic) and often asymptomatic in infancy.  \n  - **Patent Ductus Arteriosus (PDA)**: Continuous \"machinery\" murmur.  \n  - **Tetralogy of Fallot**: Cyanotic (patient has no cyanosis).  \n\n\n### **Conclusion**  \nThe most likely cause is a **ventricular septal defect (VSD)**, an abnormality of the ventricular septum (a hole between the left and right ventricles).\n\n\n**Answer: Ventricular septal defect** (or defect in the ventricular septum).  \n\n(Note: If options were provided, the correct choice would correspond to VSD.)",
    "expected_answer": "22q11 deletion",
    "time": 31.938616275787354,
    "answer_length": 1506
  },
  {
    "question": "A 30-year-old African American woman comes to the physician for the evaluation of a dry cough and chest discomfort for the past 3 days. During this period, the patient has had headaches, muscle aches, joint pain, fever, and chills. Ten days ago, she was hiking with her family in Mississippi. The patient has asthma that is treated with an albuterol inhaler. Her mother has a lung disease treated with methotrexate. The patient has smoked one pack of cigarettes daily for the past 10 years. Her temperature is 38°C (100.4°F). Physical examination shows slight wheezes throughout both lung fields. Laboratory studies and urinalysis are positive for polysaccharide antigen. Bronchoalveolar lavage using silver/PAS-staining shows macrophages filled with a dimorphic fungus with septate hyphae. Which of the following is the most likely cause of this patient's symptoms?",
    "answer": "To determine the most likely cause of the patient’s symptoms, we analyze the key clinical and laboratory findings:\n\n\n### **Key Clues**  \n1. **Endemic region**: Hiking in Mississippi (Ohio/Mississippi River valleys are endemic for *Histoplasma capsulatum*).  \n2. **Dimorphic fungus**: *Histoplasma* is dimorphic—grows as septate hyphae (mold) in the environment and small intracellular yeast in the body.  \n3. **Intracellular in macrophages**: *Histoplasma* yeast are phagocytosed by macrophages and replicate inside them (seen on silver/PAS stain of BAL).  \n4. **Polysaccharide antigen**: *Histoplasma* polysaccharide antigen is detectable in urine/serum (matches the positive lab result).  \n\n\n### **Elimination of Other Options**  \n- **Blastomyces dermatitidis**: Larger yeast with broad-based budding (not intracellular in macrophages).  \n- **Coccidioides immitis**: Endemic to the Southwest US (Arizona/New Mexico), not Mississippi.  \n- **Cryptococcus neoformans**: Non-dimorphic yeast with a capsule (India ink stain, not intracellular in macrophages).  \n\n\n**Answer: Histoplasma capsulatum**\n\n\n\\boxed{Histoplasma capsulatum}",
    "expected_answer": "Histoplasma capsulatum infection",
    "time": 28.053340196609497,
    "answer_length": 1128
  },
  {
    "question": "A 62-year-old patient has been hospitalized for a week due to a stroke. One week into the hospitalization, he develops a fever and purulent cough. His vitals include: heart rate 88/min, respiratory rate 20/min, temperature 38.4°C (101.1°F), and blood pressure 110/85 mm Hg. On physical examination, he has basal crackles on the right side of the chest. Chest radiography shows a new consolidation on the same side. Complete blood count is as follows:\nHemoglobin 16 mg/dL\nHematocrit 50%\nLeukocyte count 8,900/mm3\nNeutrophils 72%\nBands 4%\nEosinophils 2%\nBasophils 0%\nLymphocytes 17%\nMonocytes 5%\nPlatelet count 280,000/mm3\nWhat is the most likely causal microorganism?",
    "answer": "To determine the most likely causal microorganism, we analyze the patient's clinical scenario and key findings:\n\n\n### Key Clinical Features  \n- **Hospital-acquired pneumonia (HAP):** The patient developed symptoms (fever, purulent cough, consolidation) 1 week after admission (≥48 hours post-admission, meeting HAP criteria).  \n- **Risk factors:** Stroke (immobility, aspiration risk—gravity leads to basal lung involvement, as seen in right basal crackles/consolidation).  \n- **Inflammatory signs:** Mild left shift (bands 4%), purulent cough, consolidation (indicates bacterial infection).  \n\n\n### Common Pathogens for HAP  \nHAP is typically caused by **Gram-negative bacilli** or **Staphylococcus aureus**. For patients with aspiration risk (stroke), the most likely pathogens are Gram-negative rods like:  \n- **Klebsiella pneumoniae:** A frequent cause of HAP in aspiration-prone patients, associated with lobar consolidation (as seen here) and purulent sputum.  \n- Pseudomonas aeruginosa is also possible but more common in ventilated patients or those with prolonged hospitalization.  \n\nStreptococcus pneumoniae (community-acquired pneumonia) is unlikely here, given the hospital setting.  \n\n\n### Conclusion  \nThe most probable causal microorganism is **Klebsiella pneumoniae**.\n\n\n**Answer:** Klebsiella pneumoniae.",
    "expected_answer": "Staphylococcus aureus",
    "time": 50.408957958221436,
    "answer_length": 1321
  },
  {
    "question": "A 6-year-old boy is brought to the emergency department by his mother for worsening wheezing and shortness of breath over the past day. He has not had a fever, cough, vomiting, or diarrhea. He has asthma and eczema. He uses a glucocorticoid inhaler and an albuterol inhaler but has missed his medications for the past week while on vacation. He appears uncomfortable. His temperature is 36°C (96.8°F), pulse is 120/min, respirations are 40/min, and blood pressure is 100/80. Expiratory and inspiratory wheezing is heard throughout both lung fields. There are moderate intercostal and subcostal retractions and a decreased inspiratory to expiratory ratio. Nebulized albuterol and ipratropium treatments and intravenous methylprednisolone are given in the emergency department for a presumed asthma exacerbation. One hour later, the child is limp and lethargic. Magnesium sulfate is administered. His temperature is 36°C (96.8°F), pulse is 150/min, respirations are 22/min, and blood pressure is 100/70. No wheezing is heard on repeat pulmonary examination. Which of the following is the most appropriate next step in management?",
    "answer": "To determine the most appropriate next step in management, we analyze the case and key clinical clues:\n\n\n### **Case Recap**  \nA 6-year-old with asthma (missed medications) presents with an exacerbation (wheezing, retractions). He receives albuterol (beta-2 agonist), ipratropium, and IV methylprednisolone. One hour later:  \n- **Resolved wheezing** (treatment effective for airway obstruction)  \n- **Limp/lethargic** (muscle weakness/fatigue)  \n- **Tachycardia (150/min)**  \n- Normal BP and respiratory rate (22/min, appropriate for age)  \n\n\n### **Key Clinical Insight**  \nBeta-2 agonists (e.g., albuterol) cause **intracellular potassium shift** (via stimulation of Na-K-ATPase pumps), leading to **hypokalemia**. Hypokalemia presents with:  \n- Muscle weakness (limpness)  \n- Lethargy  \n- Tachycardia (due to cardiac rhythm disturbances from low K+ levels)  \n\n\n### **Next Step**  \nThe most critical next step is to **measure serum potassium concentration** to confirm hypokalemia. This guides subsequent management (e.g., potassium replacement if levels are low).\n\n\n**Answer:** Check serum potassium level. (Note: If this were a multiple-choice question, the option would likely include \"Obtain serum potassium concentration\" or similar.)\n\n\n\\boxed{Check serum potassium concentration}",
    "expected_answer": "Intubate with mechanical ventilation",
    "time": 27.29873299598694,
    "answer_length": 1285
  },
  {
    "question": "A 5-year-old female suffers from recurrent infections by Aspergillus species, Pseudomonas species, and Staphylococcus aureus. The patient's neutrophils are examined in the laboratory and they fail to react during the nitroblue tetrazolium test. Which of the following is most likely dysfunctional in this patient?",
    "answer": "To answer this question, we analyze the key clinical clues and laboratory findings:\n\n\n### **Key Observations**  \n- **Patient**: 5-year-old female with recurrent infections by *Aspergillus*, *Pseudomonas*, and *Staphylococcus aureus* (all catalase-positive pathogens).  \n- **Laboratory**: Neutrophils fail the nitroblue tetrazolium (NBT) test.  \n\n\n### **Relevance of NBT Test**  \nThe NBT test assesses the **respiratory burst** in neutrophils—their ability to generate reactive oxygen species (ROS) via the **NADPH oxidase complex**. Normal neutrophils reduce NBT to a blue formazan (positive test), but defective cells cannot (negative test).  \n\n\n### **Dysfunctional Component**  \nA negative NBT test indicates a defect in the **NADPH oxidase complex**, which is critical for producing ROS (e.g., superoxide radicals) to kill pathogens. This defect causes **Chronic Granulomatous Disease (CGD)**, where patients are susceptible to catalase-positive infections like those described.  \n\n\n**Answer: NADPH oxidase complex**\n\n\n\\boxed{NADPH oxidase complex}",
    "expected_answer": "Respiratory burst",
    "time": 16.750760078430176,
    "answer_length": 1051
  },
  {
    "question": "A 3-year-old boy presents to the emergency department with a ‘cough-like-a-seal bark’ and a high-pitched inspiratory noise that is audible without a stethoscope. His mother reports that his cough has worsened over the last few hours. The patient's blood pressure is 118/78 mm Hg, pulse is 90/min, respiratory rate is 35/min, and temperature is 38.3°C (101.1°F). On physical examination, the boy is sitting and leaning forward in apparent respiratory distress with suprasternal and intercostal retractions. Auscultation reveals inspiratory stridor without wheezing. He has a frequent barking cough and a hoarse voice when he speaks. What is a chest X-ray likely to show?",
    "answer": "The child's presentation (3-year-old, seal-like barking cough, inspiratory stridor, hoarse voice, respiratory retractions, fever) is characteristic of croup (laryngotracheobronchitis). A chest X-ray (or neck X-ray) in croup typically shows the **steeple sign**—narrowing of the subglottic airway, which appears as a pointed, steeple-like shape on the anteroposterior (AP) view due to subglottic edema.\n\n\n**Answer:** The chest X-ray is likely to show the steeple sign (subglottic airway narrowing).",
    "expected_answer": "Steeple sign",
    "time": 11.614855289459229,
    "answer_length": 497
  },
  {
    "question": "A 26-year-old woman presents to a gynecologist after a missed period. After performing a complete physical examination and a screening test for pregnancy, her gynecologist informs her that she is pregnant. She is very surprised as she has been taking oral contraceptives regularly. When the gynecologist asks her about the consumption of any other medications, she mentions that she was placed on treatment for pulmonary tuberculosis (TB) 2 months ago. Her current anti-TB regimen includes rifampin, isoniazid, pyrazinamide, and ethambutol. Which of the following mechanisms best explains the failure of oral contraceptives in this patient?",
    "answer": "The failure of oral contraceptives (OCs) in this patient is most likely due to **induction of hepatic microsomal cytochrome P450 enzymes** by rifampin, a component of her anti-tuberculosis regimen.  \n\n\n### Explanation:  \nOral contraceptives rely on sustained blood levels of estrogen and progestin to exert their contraceptive effects (e.g., suppressing ovulation, thickening cervical mucus). Rifampin is a potent inducer of the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. This enzyme system is responsible for metabolizing the active components of OCs.  \n\nWhen CYP3A4 is induced, the metabolism of estrogen and progestin is accelerated, leading to **reduced plasma concentrations** of these hormones. If their levels fall below the threshold required for contraception, ovulation and fertilization can occur, resulting in unintended pregnancy.  \n\nOther anti-TB drugs in her regimen (isoniazid, pyrazinamide, ethambutol) do not significantly induce CYP450 enzymes, so rifampin is the key culprit here.  \n\n\n**Answer:** Induction of hepatic microsomal cytochrome P450 enzymes (specifically CYP3A4) by rifampin, leading to increased metabolism and reduced bioavailability of oral contraceptive hormones.  \n\n(Note: If the question expects a concise mechanism phrase, it would be \"hepatic microsomal enzyme induction by rifampin\".)",
    "expected_answer": "Induction of CYP3A4 by rifampin leading to decreased serum levels of ethinylestradiol and progesterone",
    "time": 18.99378800392151,
    "answer_length": 1339
  },
  {
    "question": "A 4-year-old previously healthy boy presents with 4 days of intermittent vomiting and 5-6 daily loose stools. His mother noted bloody stools and decreased oral intake of food and water over the last 24 hours. He is normally in daycare; however, he has been home for the past 3 days. On physical exam his temperature is 102.2°F (39°C), blood pressure is 140/90 mmHg, pulse is 120/min, respirations are 22/min and O2 saturation is 99% on room air. He has dry mucous membranes. On abdominal exam you note diffuse tenderness to palpation without rebound or guarding. There are no masses, hepatosplenomegaly, and bowel sounds are hyperactive. Ultrasound of the right lower quadrant is negative for appendicitis. Stool is guaiac positive. He receives 15mg/kg acetaminophen and fluids are started. The next day, he complains of lower extremity weakness and tingling. On repeat exam, lower extremity strength is 3/5 with diminished patellar deep tendon reflexes. Which of the following lab findings would most likely be seen in this patient?",
    "answer": "To answer this question, we first diagnose the patient’s condition based on clinical features, then identify the associated lab findings.\n\n\n### **Step 1: Diagnose the Condition**  \nThe key clinical clues are:  \n- 4-year-old child (daycare exposure → germ transmission risk)  \n- Bloody diarrhea (after non-bloody diarrhea/vomiting)  \n- Subsequent neurological symptoms: lower extremity weakness, tingling, diminished reflexes  \n- Fever, dehydration  \n\nThis is consistent with **Shiga toxin-producing *E. coli* (STEC) infection** (e.g., O157:H7), which often progresses to **Hemolytic Uremic Syndrome (HUS)**. Shiga toxin damages endothelial cells, leading to:  \n1. Microangiopathic hemolytic anemia (MAHA)  \n2. Thrombocytopenia  \n3. Acute kidney injury (AKI)  \n\nNeurological symptoms (weakness, tingling) result from Shiga toxin-mediated neurotoxicity (peripheral neuropathy or encephalopathy).\n\n\n### **Step 2: Key Lab Findings**  \nThe classic lab abnormalities for STEC-associated HUS include:  \n- **MAHA**: Schistocytes on peripheral smear, low hemoglobin, elevated LDH (RBC breakdown), elevated unconjugated bilirubin, increased reticulocytes.  \n- **Thrombocytopenia**: Low platelet count (<150,000/μL, often <100,000/μL).  \n- **AKI**: Elevated BUN/creatinine, hematuria/proteinuria on urinalysis.  \n\n\n### **Most Likely Lab Finding**  \nAmong these, the **presence of schistocytes** (hallmark of MAHA) or **thrombocytopenia + elevated creatinine** are the most specific. For USMLE Step 2 CK, the answer is typically related to these components (e.g., \"Schistocytes on peripheral blood smear\" or \"Thrombocytopenia and increased serum creatinine\").\n\n\n**Answer:** Schistocytes on peripheral blood smear (or thrombocytopenia with elevated creatinine, depending on options—consistent with HUS triad).  \n\n(Note: If options included these, this would be the correct choice.)  \n\n**Final Answer:** Schistocytes present on peripheral blood smear (or equivalent HUS-related lab finding like thrombocytopenia and elevated creatinine).  \n\nFor the purpose of a concise answer (as per USMLE style):  \n\\boxed{Schistocytes on peripheral blood smear}  \n\n(Alternatively, if options included thrombocytopenia and elevated creatinine, that would also be correct, but schistocytes are a classic marker of MAHA in HUS.)\n\n\n\\boxed{Schistocytes on peripheral blood smear}",
    "expected_answer": "Increased cerebrospinal fluid protein with normal cell count",
    "time": 43.123619079589844,
    "answer_length": 2346
  },
  {
    "question": "A 3-week-old male newborn is brought to the physician because of an inward turning of his left forefoot. He was born at 38 weeks' gestation by cesarean section because of breech presentation. The pregnancy was complicated by oligohydramnios. Examination shows concavity of the medial border of the left foot with a skin crease just below the ball of the great toe. The lateral border of the left foot is convex. The heel is in neutral position. Tickling the lateral border of the foot leads to correction of the deformity. The remainder of the examination shows no abnormalities. X-ray of the left foot shows an increased angle between the 1st and 2nd metatarsal bones. Which of the following is the most appropriate next step in the management of this patient?",
    "answer": "To determine the most appropriate next step in management, we first identify the patient’s condition based on key clinical features:\n\n\n### Key Clinical Findings & Diagnosis  \nThe newborn has **flexible metatarsus adductus**:  \n- **Forefoot inward turning** with a **neutral heel position** (distinguishes from clubfoot, which has equinus/downward pointing heel).  \n- **Flexibility**: Deformity corrects with tickling the lateral foot border.  \n- Risk factors: Oligohydramnios (reduced uterine space) and breech presentation.  \n- X-ray: Increased angle between the 1st and 2nd metatarsals (classic for metatarsus adductus).  \n\n\n### Management of Flexible Metatarsus Adductus  \nFor flexible cases (the majority), the first-line intervention is **conservative**:  \n- Teach parents to perform **passive stretching exercises** of the forefoot outward (away from the midline) several times daily. This capitalizes on the flexibility of the deformity and promotes normal foot alignment as the infant grows.  \n\nRigid cases or those unresponsive to stretching may require splinting (e.g., Denis Browne splint) or casting later, but initial management focuses on parental-guided stretching.  \n\n\n**Answer:** Instruct the parents to perform passive stretching exercises of the left forefoot outward.  \n\n(Note: The exact wording may vary slightly, but the core action is parental education on stretching.)  \n\\boxed{Instruct the parents to perform passive stretching exercises of the left forefoot}",
    "expected_answer": "Reassurance",
    "time": 23.627140045166016,
    "answer_length": 1484
  },
  {
    "question": "A 42-year-old woman comes to the emergency department because of a 2-day history of right upper abdominal pain and nausea. She is 163 cm (5 ft 4 in) tall and weighs 91 kg (200 lb); her BMI is 34 kg/m2. Her temperature is 38.5°C (101.3°F). Physical examination shows a distended abdomen and right upper quadrant tenderness with normal bowel sounds. Laboratory studies show:\nLeukocyte count 14,000/mm3\nSerum\nTotal bilirubin 1.1 mg/dL\nAST 32 U/L\nALT 40 U/L\nAlkaline phosphatase 68 U/L\nAbdominal ultrasonography is performed, but the results are inconclusive. Cholescintigraphy shows the intrahepatic bile ducts, hepatic ducts, common bile duct, and proximal small bowel. Which of the following is the most likely cause of this patient's symptoms?\"",
    "answer": "To determine the most likely cause of the patient’s symptoms, we analyze key findings and rule out differential diagnoses:\n\n\n### **Key Patient Findings**  \n- **Demographics/Risk Factors**: 42-year-old obese woman (BMI=34, class 1 obesity)—classic risk factors for gallbladder disease (female, middle-aged, obese).  \n- **Symptoms**: 2-day right upper quadrant (RUQ) pain, nausea, fever (38.5°C).  \n- **Signs**: RUQ tenderness, leukocytosis (14,000/mm³, normal=4-10k)—indicates inflammation/infection.  \n- **Labs**: Normal liver function tests (total bilirubin=1.1mg/dL, AST=32U/L, ALT=40U/L, alkaline phosphatase=68U/L)—rules out common bile duct obstruction or hepatitis.  \n- **Imaging**: Cholescintigraphy (HIDA scan) shows intrahepatic bile ducts, hepatic ducts, common bile duct, and proximal small bowel **but not the gallbladder**.  \n\n\n### **Differential Diagnosis Ruling Out**  \n- **Choledocholithiasis**: Obstruction of common bile duct would cause elevated bilirubin and alkaline phosphatase—absent here.  \n- **Biliary colic**: No fever/leukocytosis (non-inflammatory transient cystic duct obstruction).  \n- **Acute hepatitis**: AST/ALT would be markedly elevated—not normal.  \n- **Pancreatitis**: Elevated amylase/lipase (not mentioned).  \n\n\n### **Most Likely Diagnosis**  \n**Acute cholecystitis**:  \n- The HIDA scan’s non-visualization of the gallbladder is pathognomonic (cystic duct obstruction by a stone blocks tracer entry into the gallbladder).  \n- Fits all clinical features: RUQ pain, fever, leukocytosis, and classic risk factors.  \n\n\n**Answer: Acute cholecystitis** (Note: Exact wording may vary, but this is the underlying condition.)  \n\n\\boxed{Acute cholecystitis}",
    "expected_answer": "Obstruction of the cystic duct",
    "time": 40.00038409233093,
    "answer_length": 1686
  },
  {
    "question": "A 72-year-old woman is admitted to the intensive care unit for shortness of breath and palpitations. A cardiac catheterization is performed and measurements of the left ventricular volume and pressure at different points in the cardiac cycle are obtained. The patient's pressure-volume loop (gray) is shown with a normal pressure-volume loop (black) for comparison. Which of the following is the most likely underlying cause of this patient's symptoms?",
    "answer": "To answer this question, we analyze the **clinical context** and **typical pressure-volume (PV) loop changes** for common cardiac conditions in elderly patients:\n\n\n### Key Clinical Context  \nThe patient is a 72-year-old woman with **shortness of breath (dyspnea)** and **palpitations**—classic symptoms of cardiac dysfunction in the elderly. Cardiac catheterization with PV loop analysis is used to identify the underlying cause.\n\n\n### Common PV Loop Changes & Corresponding Conditions  \nWe focus on the most probable diagnosis for this demographic:  \n\n#### Aortic Stenosis (AS)  \n- **Pathophysiology**: Calcific AS (common in elderly) causes left ventricular (LV) outflow obstruction. The LV must generate **higher systolic pressure** to eject blood against the stenotic valve.  \n- **PV Loop Features**:  \n  - Increased peak LV systolic pressure (upper limit of the loop is higher than normal).  \n  - Early stages: Preserved ejection fraction (EF); late stages: Increased end-systolic volume (ESV) if LV dysfunction develops.  \n- **Symptoms**: Dyspnea (from heart failure), palpitations (e.g., atrial fibrillation due to elevated left atrial pressure), angina, or syncope (classic triad).  \n\n\n### Why Other Options Are Less Likely  \n- **Mitral Regurgitation**: Less common as a primary cause in elderly women (calcific AS is more prevalent). PV loop shows abnormal ejection phase (regurgitant flow back to left atrium) but not the high peak LV pressure seen in AS.  \n- **Diastolic Heart Failure**: Preserved EF, but PV loop shows steeper diastolic pressure curve (stiff LV) — less likely to present with palpitations as a dominant symptom in this context.  \n- **Mitral Stenosis**: Usually due to rheumatic heart disease (less common in elderly without prior history). PV loop shows reduced LV end-diastolic volume (EDV), not elevated systolic pressure.  \n\n\n**Answer: Aortic Stenosis** (calcific type)\n\n\n\\boxed{Aortic Stenosis}",
    "expected_answer": "Increased ventricular wall stiffness",
    "time": 42.513659954071045,
    "answer_length": 1927
  },
  {
    "question": "A 22-year-old woman is brought to the emergency department because of a 2-day history of fever, intermittent rigors, and night sweats. She also has a 1-month history of progressive fatigue. Five weeks ago, she was hospitalized and received intravenous antibiotics for treatment of bacterial meningitis while visiting relatives in Guatemala. Her temperature is 39.4°C (102.9°F), pulse is 130/min, and blood pressure is 105/70 mm Hg. Examination shows pallor and scattered petechiae and ecchymoses. Laboratory studies show a hemoglobin concentration of 9.0 g/dL, a leukocyte count of 1,100/mm3 with 30% segmented neutrophils, and a platelet count of 20,000/mm3 . Blood cultures grow coagulase-negative staphylococci. The patient was most likely treated with which of the following antibiotics?",
    "answer": "To solve this question, we analyze the patient’s key clinical features and link them to an antibiotic associated with her presentation:\n\n\n### **Key Clinical Clues**  \n- **History**: 5 weeks prior, treated with IV antibiotics for bacterial meningitis in Guatemala (resource-limited setting).  \n- **Current Presentation**: Fever, rigors, night sweats + **pancytopenia** (low hemoglobin: 9g/dL; leukopenia: 1,100/mm³; thrombocytopenia: 20,000/mm³).  \n- **Blood cultures**: Coagulase-negative staphylococci (may be secondary to immunosuppression from pancytopenia).  \n\n\n### **Antibiotic Link to Pancytopenia**  \nThe patient’s pancytopenia is consistent with **aplastic anemia**—a rare but severe idiosyncratic reaction to **chloramphenicol**.  \n\nChloramphenicol is:  \n1. Effective against common meningitis pathogens (e.g., *Streptococcus pneumoniae*, *Neisseria meningitidis*, *Haemophilus influenzae*).  \n2. Often used in resource-limited settings (like Guatemala) due to low cost.  \n3. Associated with aplastic anemia that can occur **weeks after exposure** (matches the 5-week timeline here).  \n\n\n### **Other Antibiotics Ruled Out**  \n- Ceftriaxone/vancomycin/ampicillin: Not typically linked to aplastic anemia.  \n\n\n**Answer: Chloramphenicol**\n\n\n\\boxed{Chloramphenicol}",
    "expected_answer": "Chloramphenicol",
    "time": 26.56525707244873,
    "answer_length": 1270
  },
  {
    "question": "An otherwise healthy 50-year-old man comes to the physician because of a 6-month history of increasingly frequent episodes of upper abdominal pain, nausea, vomiting, and diarrhea. He has had a 3.2-kg (7-lb) weight loss during this time. Physical examination shows bilateral pitting pedal edema. An endoscopy shows prominent rugae in the gastric fundus. Biopsy shows parietal cell atrophy. Which of the following is the most likely underlying cause?",
    "answer": "To determine the underlying cause, let’s analyze the key clinical and pathological findings and correlate them with known conditions:\n\n\n### **Key Findings**  \n- 50-year-old man with 6-month history: upper abdominal pain, nausea/vomiting, diarrhea, weight loss (3.2kg), bilateral pitting edema.  \n- Endoscopy: prominent (giant) rugae in gastric fundus.  \n- Biopsy: parietal cell atrophy.  \n\n\n### **Pathophysiological Clues**  \n1. **Parietal cell atrophy**: Reduced hydrochloric acid (HCl) and intrinsic factor secretion → impaired protein digestion and potential malabsorption.  \n2. **Prominent rugae**: Suggests hyperplasia of the gastric mucosa (specifically mucus-secreting cells).  \n3. **Bilateral pitting edema**: Indicates hypoproteinemia (low albumin), likely from **protein loss** (gastropathy) due to a leaky, hyperplastic gastric mucosa.  \n\n\n### **Differential Diagnosis**  \n- **Autoimmune gastritis**: Causes parietal cell atrophy but typically affects the fundus/body without giant rugae or protein loss edema (main complication: pernicious anemia from intrinsic factor deficiency).  \n- **Menetrier’s disease**: Characterized by **giant rugae** (hyperplasia of mucus-secreting foveolar cells), which compress the glandular layer → parietal cell atrophy. Key symptoms include protein loss gastropathy (edema), malabsorption (weight loss, diarrhea), and abdominal discomfort. This perfectly matches the patient’s findings.  \n- **Helicobacter pylori gastritis**: Usually affects the antrum first and does not cause giant rugae or protein loss edema.  \n\n\n### **Conclusion**  \nThe most likely underlying cause is **Menetrier’s disease**, driven by hyperplasia of gastric mucus cells leading to prominent rugae, parietal cell atrophy, and protein loss-induced edema.\n\n\n**Answer: Menetrier's disease** (or if asked for the mechanism: Hyperplasia of gastric foveolar cells leading to parietal cell atrophy and protein loss gastropathy).  \n\n(Note: If options included \"Autoimmune destruction of parietal cells\" vs \"Menetrier’s disease\", Menetrier’s is the correct choice here due to the prominent rugae and edema.)  \n\nBut given standard question framing, the expected answer is **Menetrier's disease**.  \n\n\\boxed{Menetrier's disease}",
    "expected_answer": "Proliferation of gastric mucus-producing cells",
    "time": 55.65810012817383,
    "answer_length": 2235
  },
  {
    "question": "A 27-year-old man presents to the emergency department. He was brought in by staff from the homeless shelter when they found him unresponsive. The patient is a known IV drug abuser but otherwise has an unknown past medical history. He currently attends a methadone clinic. His temperature is 99.5°F (37.5°C), blood pressure is 97/48 mmHg, pulse is 140/min, respirations are 29/min, and oxygen saturation is 98% on room air. Initial laboratory values are shown below.\n\nSerum:\nNa+: 139 mEq/L\nCl-: 100 mEq/L\nK+: 6.3 mEq/L\nHCO3-: 17 mEq/L\nGlucose: 589 mg/dL\n\nThe patient is given treatment. After treatment, his temperature is 99.5°F (37.5°C), blood pressure is 117/78 mmHg, pulse is 100/min, respirations are 23/min, and oxygen saturation is 98% on room air. His laboratory values are seen below.\n\nSerum:\nNa+: 139 mEq/L\nCl-: 100 mEq/L\nK+: 4.3 mEq/L\nHCO3-: 19 mEq/L\nGlucose: 90 mg/dL\n\nWhich of the following is the best next step in management?",
    "answer": "To determine the best next step in management, we first analyze the patient’s clinical course and key findings:\n\n\n### **Step 1: Identify the Initial Diagnosis**  \nThe patient presents with **diabetic ketoacidosis (DKA)**—characterized by:  \n- Severe hyperglycemia (glucose = 589 mg/dL)  \n- Metabolic acidosis (HCO₃⁻ = 17 mEq/L, anion gap = 139 - (100+17) = 22, elevated)  \n- Hyperkalemia (K = 6.3 mEq/L, typical in DKA due to insulin deficiency and acidosis)  \n- Tachycardia/tachypnea (compensatory for acidosis)  \n\nDKA triggers often include infection (the patient’s mild fever and IV drug use history raise suspicion for this).\n\n\n### **Step 2: Evaluate Response to Treatment**  \nAfter initial therapy (IV fluids, insulin), the patient shows improvement:  \n- Glucose normalized (90 mg/dL)  \n- K corrected (4.3 mEq/L)  \n- Vitals stabilized  \n\nHowever, **anion gap remains elevated** (139 - (100+19) = 20) and HCO₃⁻ is still subnormal (19 mEq/L), indicating ongoing ketoacidosis (ketone production persists despite normal glucose).\n\n\n### **Step 3: Determine Next Management Step**  \nIn DKA, insulin infusion is continued until:  \n1. Anion gap closes (<12)  \n2. HCO₃⁻ ≥ 18-20 mEq/L  \n\nSince glucose is now normal (90 mg/dL), **dextrose must be added to IV fluids** to prevent hypoglycemia while continuing insulin to resolve residual ketogenesis.\n\n\n### **Conclusion**  \nThe best next step is to **continue IV insulin infusion with dextrose-containing fluids** to maintain euglycemia and clear remaining ketones.\n\n\n**Answer:** Continue IV insulin infusion and add dextrose to the intravenous fluids. (Note: This aligns with standard DKA management guidelines for persistent acidosis after glucose normalization.)  \n\n(If this were a multiple-choice question, the correct option would reflect this principle.)\n\n\n\\boxed{Continue IV insulin infusion with dextrose supplementation}",
    "expected_answer": "Insulin, potassium, IV fluids, and glucose",
    "time": 59.67983603477478,
    "answer_length": 1873
  },
  {
    "question": "A 67-year-old man who was diagnosed with arthritis 16 years ago presents with right knee swelling and pain. His left knee was swollen a few weeks ago, but now with both joints affected, he has difficulty walking and feels frustrated. He also has back pain which makes it extremely difficult to move around and be active during the day. He says his pain significantly improves with rest. He also suffers from dandruff for which he uses special shampoos. Physical examination is notable for pitting of his nails. Which of the following is the most likely diagnosis?",
    "answer": "To determine the most likely diagnosis, we analyze the patient’s key clinical features and match them to common arthritic conditions:\n\n\n### **Key Clinical Findings**  \n- 67-year-old man with 16-year history of arthritis  \n- Migratory/alternating joint swelling (left knee → right knee)  \n- Back pain improved with rest  \n- **Nail pitting** (classic cutaneous sign of psoriasis)  \n- **Dandruff** (likely scalp psoriasis, a common manifestation of psoriasis)  \n\n\n### **Differential Diagnosis**  \n1. **Psoriatic Arthritis**:  \n   - Strongly associated with psoriasis (nail pitting, scalp involvement are diagnostic clues).  \n   - Can affect large joints (knees) and the spine (axial involvement → back pain).  \n   - Inflammatory arthritis, but symptoms may vary (some patients report pain relief with rest, especially if combined with degenerative changes over time).  \n\n2. **Rheumatoid Arthritis**:  \n   - Symmetric joint involvement and morning stiffness >1 hour are typical, but **nail pitting is not a feature**.  \n\n3. **Osteoarthritis**:  \n   - Degenerative, worsens with activity and improves with rest, but lacks nail pitting or psoriasis-related skin findings.  \n\n4. **Ankylosing Spondylitis**:  \n   - Axial involvement (back pain) but no nail pitting or scalp psoriasis.  \n\n\n### **Conclusion**  \nThe combination of nail pitting, scalp psoriasis (dandruff), and inflammatory joint/spine involvement points to **psoriatic arthritis**.\n\n\n**Answer: Psoriatic arthritis**",
    "expected_answer": "Psoriatic arthritis",
    "time": 27.686429023742676,
    "answer_length": 1472
  },
  {
    "question": "A 65-year-old woman schedules an appointment with her physician for evaluation of weight loss and weakness. The weakness is more noticeable when climbing stairs and combing hair. The weakness improves after brief exercise. She also has bladder incontinence for the past 4 weeks and was given an anticholinesterase agent with no improvement. What is the most likely cause of the symptoms?",
    "answer": "To determine the most likely cause of the patient’s symptoms, let’s analyze the key findings and match them to a clinical condition:\n\n\n### **Key Symptoms Recap**  \n- **65-year-old woman** with:  \n  - Proximal weakness (worse climbing stairs/combing hair, affects upper/lower proximal muscles).  \n  - Weakness **improves after brief exercise** (opposite of myasthenia gravis).  \n  - Bladder incontinence (autonomic dysfunction).  \n  - Weight loss (suggests underlying malignancy).  \n  - No response to anticholinesterase agents.  \n\n\n### **Differential Diagnosis & Rationale**  \n- **Myasthenia Gravis (MG):** Ruled out. MG causes weakness that *worsens* with activity (fatigability) and responds to anticholinesterase agents—neither is true here.  \n- **Lambert-Eaton Myasthenic Syndrome (LEMS):** **Most likely.**  \n  - **Pathophysiology:** Autoantibodies against presynaptic voltage-gated calcium channels (VGCCs) → reduced acetylcholine (ACh) release at neuromuscular junctions.  \n  - **Exercise effect:** Brief exercise increases calcium accumulation in presynaptic terminals → improved ACh release → temporary weakness relief.  \n  - **Autonomic symptoms:** VGCC antibodies affect autonomic nerves → urinary incontinence, dry mouth, etc.  \n  - **Paraneoplastic association:** LEMS is often linked to small cell lung cancer (SCLC), which explains the weight loss (malignancy-related cachexia).  \n\n\n**Answer:** Lambert-Eaton Myasthenic Syndrome (likely paraneoplastic, associated with small cell lung cancer).  \n\n\\boxed{Lambert-Eaton Myasthenic Syndrome}",
    "expected_answer": "Paraneoplastic syndrome from small cell carcinoma of the lung",
    "time": 21.844156980514526,
    "answer_length": 1553
  },
  {
    "question": "A 3-month-old boy presents to his pediatrician with persistent diarrhea, oral candidiasis, and signs and symptoms suggestive of respiratory syncytial virus (RSV) pneumonia. His weight is in the 10th percentile. He is being evaluated for an immunodeficiency disease. Laboratory results for the HIV are negative by PCR. Which of the following is the most likely cause of these findings in this patient?",
    "answer": "To determine the most likely cause of the patient’s findings, let’s analyze the key clinical features and rule out differential diagnoses:\n\n\n### **Patient Summary**  \n3-month-old boy with:  \n- Persistent diarrhea, oral candidiasis (fungal infection), RSV pneumonia (viral infection)  \n- Failure to thrive (weight in 10th percentile)  \n- Immunodeficiency evaluation (HIV PCR negative)  \n\n\n### **Key Differential Diagnoses & Ruling Out**  \n1. **HIV infection**: Explicitly ruled out by negative PCR.  \n2. **X-linked agammaglobulinemia (Bruton’s)**: Presents later (6-9 months) when maternal antibodies wane; unlikely at 3 months.  \n3. **DiGeorge syndrome**: T-cell deficiency due to thymic hypoplasia, but typically associated with cardiac anomalies, hypocalcemia—no mention here.  \n4. **Chronic Granulomatous Disease (CGD)**: Phagocyte dysfunction, presents with recurrent bacterial/fungal infections but not this combination of viral/fungal/GI issues at 3 months.  \n5. **Wiskott-Aldrich syndrome**: X-linked, but requires thrombocytopenia/eczema (absent here).  \n\n\n### **Most Likely Diagnosis: Severe Combined Immunodeficiency (SCID)**  \nSCID is a **combined B- and T-cell deficiency** (critical for fighting viral, fungal, and bacterial infections). It presents in the first 3-6 months of life with:  \n- Recurrent severe infections (viral: RSV; fungal: oral candidiasis; GI: persistent diarrhea)  \n- Failure to thrive (from chronic inflammation/infections)  \n- Absence of HIV (ruled out here)  \n\n\n**Answer: Severe Combined Immunodeficiency (SCID)**  \n\n\\boxed{Severe Combined Immunodeficiency (SCID)}",
    "expected_answer": "Defective T cell function",
    "time": 22.835106134414673,
    "answer_length": 1600
  },
  {
    "question": "A 53-year-old man with recurrent pancreatic adenocarcinoma is enrolled in a clinical trial for a novel chemotherapeutic agent that his physician believes may be beneficial to his condition. The novel drug was previously tested in a small population and is now undergoing a larger phase 3 trial in preparation for FDA approval. A dose-response trial had the following results:\n\n10 mg dose - 6/59 patients demonstrated improvement\n20 mg dose - 19/49 patients demonstrated improvement\n30 mg dose - 26/53 patients demonstrated improvement\n40 mg dose - 46/51 patients demonstrated improvement\n\nThe same trial also had the following safety profile:\n\n20 mg dose - 5/49 patients had a treatment related adverse event\n40 mg dose - 11/51 patients had a treatment related adverse event\n60 mg dose - 15/42 patients had a treatment related adverse event\n80 mg dose - 23/47 patients had a treatment related adverse event\n100 mg dose - 47/52 patients had a treatment related adverse event\n\nBased on this study, which of the following represents the most likely therapeutic index for this novel chemotherapeutic agent?",
    "answer": "To determine the therapeutic index (TI) of the novel chemotherapeutic agent, we first recall that **TI = TD₅₀ / ED₅₀**, where:  \n- **ED₅₀**: Dose effective in 50% of the population.  \n- **TD₅₀**: Dose causing toxicity (adverse events) in 50% of the population.  \n\n\n### Step 1: Calculate ED₅₀  \nFrom the dose-response data:  \n- 20 mg: ~38.8% improvement  \n- 30 mg: ~49.1% improvement  \n\nED₅₀ is the dose where 50% of patients improve. Since 30 mg yields ~49.1% improvement (nearly 50%), **ED₅₀ ≈ 30 mg**.  \n\n\n### Step 2: Calculate TD₅₀  \nFrom the safety profile data:  \n- 60 mg: ~35.7% adverse events  \n- 80 mg: ~48.9% adverse events  \n\nTD₅₀ is the dose where 50% of patients experience adverse events. Since 80 mg yields ~48.9% adverse events (nearly 50%), **TD₅₀ ≈ 80 mg**.  \n\n\n### Step 3: Compute TI  \nTI = TD₅₀ / ED₅₀ ≈ 80 mg / 30 mg ≈ 2.67, which rounds to **3** (the closest whole number, typical for clinical contexts).  \n\n\n**Answer: 3**",
    "expected_answer": "2.67",
    "time": 44.728679895401,
    "answer_length": 943
  },
  {
    "question": "A 67-year-old male is seen by neurology after he was noticed to be speaking strangely by his family. After acute treatment with tissue plasminogen activator (tPA), the patient is able to recover most of his speech. Subsequent neurologic exam finds that the patient is fluent while speaking and is able to comprehend both one and two step instructions. Noticeably the patient remains unable to complete tasks involving verbal repetition. Residual damage to which of the following structures is most likely responsible for this patient's syndrome?",
    "answer": "To determine the responsible structure, we analyze the patient’s syndrome using key aphasia principles:\n\n\n### **Key Clinical Features of the Patient**  \n- **Fluent speech**: Rules out Broca’s aphasia (non-fluent, effortful speech).  \n- **Intact comprehension**: Rules out Wernicke’s aphasia (poor comprehension, nonsensical speech).  \n- **Impaired verbal repetition**: This is the defining deficit here.  \n\n\n### **Aphasia Syndrome Matching**  \nThe combination of fluent speech, intact comprehension, and impaired repetition is **conduction aphasia**.  \n\nConduction aphasia arises from damage to the **arcuate fasciculus**—a white matter tract connecting Broca’s area (frontal lobe, speech production) and Wernicke’s area (temporal lobe, speech comprehension). This tract is critical for repeating spoken language: it transmits auditory information processed by Wernicke’s area to Broca’s area for verbal output. When damaged, repetition fails even if both Broca’s and Wernicke’s areas are functional.  \n\n\n**Answer: Arcuate fasciculus**",
    "expected_answer": "Arcuate fasciculus",
    "time": 15.734822988510132,
    "answer_length": 1035
  },
  {
    "question": "A 27-year-old woman presents to the office with concerns about her long struggle with her physical appearance since adolescence. She says she has always been \"large\" and was constantly targeted by her classmates and coworkers for being so. Her main concern at the moment is her acne and unwanted facial hair on her upper lip, for which she often visits a local spa. She has tried numerous diet plans, exercise regimens, and cosmetic products with little to no effect. Recently, she underwent a glucose tolerance test that showed a plasma glucose level of 160 mg/dL (8.9 mmol/L) after 2 hours of a 75 g dose of oral glucose. She has a family history of type 2 diabetes mellitus and a menstrual cycle that occurs every 45 days. Her pulse is 72/min and the blood pressure is 138/80 mm Hg. On physical examination, her height is 160 cm (5 ft 3 in) and her weight is 85 kg (187 lb), and she has severe inflammatory acne over the cheeks and forehead and dark coarse hairs on the back. What is the most likely diagnosis of this patient?",
    "answer": "The most likely diagnosis is **Polycystic Ovary Syndrome (PCOS)**.\n\n\n### Key Reasoning:  \nThe patient’s presentation aligns with the Rotterdam criteria for PCOS (requiring ≥2 of 3 features):  \n1. **Oligo-ovulation**: Menstrual cycles every 45 days (normal = ~28 days).  \n2. **Clinical hyperandrogenism**: Severe acne and hirsutism (dark coarse back hair, upper lip hair).  \n3. **Insulin resistance/metabolic dysfunction**: Obese BMI (~33.2), impaired glucose tolerance (2-hour post-75g glucose =160 mg/dL), and family history of type 2 diabetes—common associations with PCOS.  \n\nOther conditions (e.g., Cushing syndrome, non-classic congenital adrenal hyperplasia) are less likely: no signs of moon face/buffalo hump (Cushing) or early onset symptoms (CAH) are present. PCOS is the most prevalent cause of these findings in reproductive-age women.\n\n\n**Answer: Polycystic Ovary Syndrome (PCOS)**",
    "expected_answer": "Polycystic ovarian syndrome (PCOS)",
    "time": 24.475996732711792,
    "answer_length": 894
  },
  {
    "question": "А 43-уеаr-old mаn рrеѕеntѕ wіth tіnglіng аnd numbnеѕѕ of the lowеr lіmbѕ for 2 wееkѕ. Не also сomрlаіnѕ of реrѕіѕtеnt раіn in his legs whісh is not relieved by over-the-counter analgesics. Past medical history is significant for type 2 dіаbеtes mellitus for 2 уеаrѕ, inconsistently managed with mеtformіn аnd glіmеріrіdе. Оn physical ехаmіnаtіon, thеrе іѕ dесrеаѕеd ѕеnѕаtіon to pain in both lower lіmbs, but deep tеndon rеflехеѕ аrе іntасt. Ніѕ vіtаl ѕіgnѕ include: blood рrеѕѕurе 122/84 mm Нg, tеmреrаturе 36.7°C (98.1°F), and rеѕріrаtorу rаtе 10/mіn. His ankle-brachial pressure index (ABPI) on the right side is 1.1. His blood sugar analyses are as follows:\nFasting 141 mg/ dL\n2 hours Post-Prandial 235 mg/ dL\nHbA1c 8.1%\nWhich of the following is the best measure to prevent the progression of the symptoms present in this patient?",
    "answer": "To determine the best measure to prevent progression of the patient’s symptoms, we first identify the underlying condition: **diabetic distal symmetric polyneuropathy**.  \n\n### Key Observations:  \n- The patient has type 2 diabetes with poor glycemic control (HbA1c = 8.1%, well above the target <7% for diabetics).  \n- Symptoms (tingling, numbness, persistent pain) and exam findings (decreased pain sensation) are classic for diabetic neuropathy.  \n- Normal ankle-brachial pressure index (ABPI =1.1) rules out peripheral arterial disease as the primary cause.  \n\n### Critical Insight:  \nThe most effective intervention to slow or prevent progression of diabetic neuropathy is **tight glycemic control**. Pain management (e.g., gabapentin, duloxetine) addresses symptoms but does not halt disease progression.  \n\n### Conclusion:  \nThe best measure is optimizing glycemic control (e.g., consistent adherence to diabetes medications, adjusting therapy to achieve target HbA1c levels).  \n\n**Answer:** Optimizing glycemic control (e.g., achieving and maintaining target HbA1c levels through consistent diabetes management).  \n\n(Note: If specific options were provided, the correct choice would align with this principle—e.g., \"Improve adherence to antidiabetic medications to achieve target glycemic control\" or \"Initiate intensification of diabetes therapy to lower HbA1c.\")  \n\n**Final Answer:** Improve glycemic control (e.g., achieve target HbA1c through consistent diabetes management).  \n\\boxed{Improve glycemic control}",
    "expected_answer": "Strict blood glucose control",
    "time": 19.81516695022583,
    "answer_length": 1521
  },
  {
    "question": "A one-day-old male is evaluated in the hospital nursery for bilious vomiting. The patient has urinated multiple times since birth but has not yet passed meconium. He was born at 38 weeks gestation to a 36-year-old gravida 3 via vaginal delivery. The pregnancy was complicated by gestational diabetes. The patient’s mother received routine prenatal care and declined first trimester screening. She subsequently underwent a quadruple screen at 15 weeks gestation that demonstrated decreased maternal serum alpha-fetoprotein (AFP), increased beta-hCG, decreased unconjugated estriol, and increased inhibin A. Her last ultrasound prior to onset of labor demonstrated an amniotic fluid index (AFI) of 28 cm. The patient’s two older siblings are both healthy. The patient’s temperature is 97.8°F (36.6°C), blood pressure is 58/37 mmHg, pulse is 166/min, and respirations are 38/min. On physical exam, the patient is in moderate distress. His abdomen is firm and distended with hypoactive bowel sounds.\n\nWhich of the following is the most likely etiology of this fetus’s presentation?",
    "answer": "To determine the most likely etiology, we analyze the **prenatal history** and **newborn presentation** together:\n\n\n### Key Prenatal Findings  \n- **Quadruple screen results**: Decreased AFP, decreased unconjugated estriol, increased beta-hCG, increased inhibin A → Classic for **trisomy 21 (Down syndrome)**.  \n- **Amniotic fluid index (AFI) = 28 cm**: Normal AFI is 5-25 cm → **Polyhydramnios** (excess amniotic fluid), which occurs when the fetus cannot swallow/absorb fluid (e.g., GI obstruction).  \n\n\n### Key Newborn Presentation  \n- **Bilious vomiting**: Suggests obstruction **distal to the ampulla of Vater** (bile is present).  \n- **No meconium passage**: Indicates complete GI tract obstruction.  \n- **Firm, distended abdomen**: Consistent with intestinal obstruction.  \n\n\n### Link Between Prenatal and Newborn Findings  \nDuodenal atresia (congenital obstruction of the duodenum) is **strongly associated with Down syndrome** (~30% of cases). It causes:  \n- **Polyhydramnios**: Impaired fluid passage through the duodenum → fetus cannot absorb amniotic fluid.  \n- **Newborn symptoms**: Bilious vomiting (obstruction after bile duct entry), no meconium, abdominal distension.  \n\n\n**Answer: Duodenal atresia** (secondary to trisomy 21, as indicated by the quadruple screen).  \n\n\\boxed{Duodenal\\ atresia}",
    "expected_answer": "Duodenal atresia",
    "time": 34.32299494743347,
    "answer_length": 1310
  },
  {
    "question": "A healthy 23-year-old male is undergoing an exercise stress test as part of his physiology class. If blood were to be sampled at different locations before and after the stress test, which area of the body would contain the lowest oxygen content at both time points?",
    "answer": "To determine the area with the lowest oxygen content in blood at both rest and exercise, we analyze the oxygenation pathway of blood:  \n\nOxygenated blood from the lungs travels to the left heart and is pumped to tissues via the aorta. Tissues extract oxygen, so deoxygenated blood returns to the right heart via the vena cava. The right ventricle then pumps this deoxygenated blood to the lungs through the pulmonary artery.  \n\nKey observation: The pulmonary artery carries the most deoxygenated blood in the body at all times (both rest and exercise). During exercise, tissues use more oxygen, further reducing the oxygen content of venous blood—but the pulmonary artery still contains the lowest oxygen content, as it transports this maximally deoxygenated blood to the lungs for reoxygenation.  \n\n**Answer:** Pulmonary artery.",
    "expected_answer": "Coronary sinus",
    "time": 25.37034296989441,
    "answer_length": 829
  },
  {
    "question": "A 45-year-old G5P4105 presents to her gynecologist’s office with six months of increasingly heavy periods. She now soaks one super absorbent tampon every two hours for five days each cycle. Her cycles have also become irregular, with intermenstrual bleeding for the last two months. She now experiences significant dysmenorrhea, requiring 400 mg ibuprofen every four hours for the majority of each menses. In addition, she reports new onset mild dyspareunia with intercourse and a “heavy feeling” in her pelvis. She has also noticed increased urinary frequency but denies bowel changes. The patient has a past medical history of obesity and type II diabetes on metformin. Her last child was born four years ago, and she has had five spontaneous vaginal deliveries. At this office visit, temperature is 98.5°F (36.9°C), blood pressure is 137/84 mmHg, pulse is 87/min, and respirations are 14/min. Which of the following physical exam findings is most likely to be present in this patient?",
    "answer": "To determine the most likely physical exam finding, we first analyze the patient’s clinical presentation and identify the underlying condition:\n\n\n### **Step 1: Key Clinical Features**  \nThe patient is a 45-year-old woman with:  \n- **Reproductive history**: G5P4105 (multiple pregnancies/deliveries, a risk factor for uterine leiomyomas).  \n- **Symptoms**:  \n  - Heavy, irregular menstrual bleeding (menorrhagia + metrorrhagia).  \n  - Pelvic pressure (\"heavy feeling\"), dyspareunia, and urinary frequency (bladder compression).  \n  - Dysmenorrhea (though less specific).  \n- **Comorbidities**: Obesity, type II diabetes (additional risk factors for fibroids).  \n\n\n### **Step 2: Most Likely Diagnosis**  \nThe constellation of symptoms (heavy bleeding, pelvic pressure, bladder compression) plus risk factors (multiple pregnancies, obesity) strongly suggests **uterine leiomyomas (fibroids)**. Fibroids are benign smooth muscle tumors of the uterus, common in reproductive-aged women.  \n\n\n### **Step 3: Classic Physical Exam Finding for Fibroids**  \nUterine leiomyomas typically cause the uterus to be **enlarged and irregularly contoured** (due to discrete, firm masses within the myometrium). This is the hallmark physical exam finding for this condition.  \n\n\n**Answer:** An enlarged, irregularly shaped uterus.  \n\n(Note: Exact phrasing may vary, but the core finding is an irregularly enlarged uterus.)",
    "expected_answer": "Globular 10-week sized uterus",
    "time": 24.78606629371643,
    "answer_length": 1402
  },
  {
    "question": "A man is brought into the emergency department by the police department. The officer state that the man has been arrested multiple times for public alcohol intoxication, but recently became homeless. On exam, the man is behaving erratically. His vitals are all within normal limits. He appears confused and has a slurred speech. On gait exam, the patient is ataxic and cannot stand without support for more than a few seconds. Labs return with the following values: Na 140, K 4, Cl 106, BUN 8, Cr 2. His ABG has pH 7.3, PaCO2 13mm, PaO2 130mm, HCO3 7. His urinalysis is shown in Figure 1. Blood salicylate levels return as normal. While you await other diagnostic tests, which of the following should be administered next to treat this patient?",
    "answer": "To answer this question, we first analyze the patient’s presentation and lab findings to identify the underlying condition, then determine the appropriate immediate treatment.\n\n\n### **Step 1: Key Clinical & Lab Findings**  \n- **History**: Homeless, chronic alcohol use, erratic behavior, confusion, slurred speech, ataxia.  \n- **Vitals**: Normal (no fever/sepsis clues).  \n- **Acid-Base Status**:  \n  - pH = 7.3 (acidosis).  \n  - HCO₃ = 7 mEq/L (severe metabolic acidosis).  \n  - PaCO₂ =13 mmHg (compensatory respiratory alkalosis via hyperventilation).  \n- **High Anion Gap**: Na - (Cl + HCO₃) =140 - (106+7)=27 (normal=8-12 → HAGMA).  \n- **Salicylate levels**: Normal (rules out aspirin overdose).  \n\n\n### **Step 2: Diagnosis**  \nThe combination of **HAGMA + respiratory alkalosis**, along with the patient’s homeless/alcohol use history, points to **methanol or ethylene glycol poisoning** (both are in the MUDPILES mnemonic for HAGMA: Methanol/Ethylene glycol). These toxins are often accessible to homeless individuals and cause metabolic acidosis via toxic metabolites (formic acid for methanol, oxalate for ethylene glycol) + compensatory hyperventilation.  \n\n\n### **Step3: Immediate Treatment**  \nThe critical first step to halt toxin metabolism is to inhibit **alcohol dehydrogenase (ADH)**—the enzyme that converts methanol/ethylene glycol into toxic byproducts. The preferred antidote is **fomepizole** (4-methylpyrazole), which is safe and effective (avoids the need for frequent ethanol level monitoring).  \n\n\n**Answer: Fomepizole** (or ethanol if fomepizole is unavailable, but fomepizole is first-line in modern practice).  \n\n\\boxed{Fomepizole}",
    "expected_answer": "Fomepizole",
    "time": 55.920552015304565,
    "answer_length": 1659
  },
  {
    "question": "A medical research study is evaluating an investigational novel drug (medication 1) compared with standard therapy (medication 2) in patients presenting to the emergency department with myocardial infarction (MI). The study enrolled a total of 3,000 subjects, 1,500 in each study arm. Follow-up was conducted at 45 days post-MI. The following are the results of the trial:\nEndpoints Medication 1 Medication 2 P-Value\nPrimary: death from cardiac causes 134 210 0.03\nSecondary: hyperkalemia 57 70 0.4\nWhat is the number needed to treat (NNT) for the primary endpoint of death from cardiac causes? (Round to the nearest whole number.)",
    "answer": "To calculate the Number Needed to Treat (NNT) for the primary endpoint of death from cardiac causes, follow these steps:\n\n\n### Step 1: Calculate Event Rates  \n- **Medication 1 (Treatment)**: Event rate = number of cardiac deaths / total subjects = \\(134/1500 ≈ 0.0893\\) (8.93%).  \n- **Medication 2 (Control)**: Event rate = \\(210/1500 = 0.14\\) (14%).  \n\n\n### Step 2: Compute Absolute Risk Reduction (ARR)  \nARR = Control event rate - Treatment event rate = \\(0.14 - 0.0893 = 0.0507\\).  \n\n\n### Step3: Calculate NNT  \nNNT = \\(1 / ARR = 1 / 0.0507 ≈ 19.7\\), rounded to the nearest whole number is **20**.  \n\n\nAnswer: 20.",
    "expected_answer": "20",
    "time": 24.397850036621094,
    "answer_length": 617
  },
  {
    "question": "A 55-year-old man comes to the physician because of a 6-week history of tingling pain in the sole of his right foot when he raises it above chest level during exercises. He reports that he started exercising regularly 2 months ago and that his right calf cramps when he uses the incline feature on the treadmill, forcing him to take frequent breaks. The pain completely disappears after resting for a few minutes. He has an 8-year history of type 2 diabetes mellitus. He has smoked two packs of cigarettes daily for 34 years. His only medication is metformin. His pulse is 82/min, and blood pressure is 170/92 mm Hg. Straight leg raise test elicits pallor and tingling pain in the right foot. There is no pain in the back. His muscle strength is normal. Femoral pulses are palpable; right pedal pulses are absent. Which of the following is the most likely diagnosis?",
    "answer": "To determine the most likely diagnosis, we analyze the patient’s key clinical features and risk factors:\n\n\n### **Key Clinical Findings**  \n- **Risk factors**: 8-year type 2 diabetes mellitus (DM), 34-year history of heavy smoking (2 packs/day), hypertension (170/92 mmHg).  \n- **Symptoms**:  \n  - Exercise-induced right calf cramps (relieved by rest: classic **intermittent claudication**).  \n  - Tingling pain in the right sole when raising the foot above chest level (pallor with elevation: vascular insufficiency).  \n- **Signs**:  \n  - Absent right pedal pulses (femoral pulses are palpable, ruling out proximal aortoiliac disease).  \n  - Straight leg raise test elicits pallor (vascular, not neurogenic—no back pain or muscle weakness).  \n\n\n### **Ruling Out Alternatives**  \n- **Diabetic neuropathy**: Typically symmetric, burning pain, unrelated to exercise/elevation, no absent pulses or pallor.  \n- **Lumbar radiculopathy**: Neurogenic pain (radiating, weakness/reflex changes), no pallor, and back pain is absent here.  \n- **Deep vein thrombosis**: Swelling/redness, pain at rest, pulses usually preserved (not absent).  \n\n\n### **Conclusion**  \nAll findings align with **peripheral arterial disease (PAD)** (or peripheral arterial occlusive disease, PAOD), caused by atherosclerotic narrowing of lower extremity arteries (consistent with risk factors and vascular symptoms/signs).\n\n\n**Answer: Peripheral Arterial Disease** (or **Peripheral Arterial Occlusive Disease**)  \n\n(Note: In clinical contexts, \"Peripheral Arterial Disease\" is the standard term for this condition.)  \n\n\\boxed{Peripheral Arterial Disease}",
    "expected_answer": "Femoropopliteal artery stenosis",
    "time": 26.3960702419281,
    "answer_length": 1620
  },
  {
    "question": "A 29-year-old primigravid woman at 35 weeks' gestation is admitted to the hospital in labor. She has no history of serious medical illness. She has had an uncomplicated pregnancy. Her last ultrasound at 22 weeks' gestation was normal. On admission, fetal heartbeats cannot be detected by fetal doppler monitor. Ultrasound shows decreased amniotic fluid levels and no evidence of fetal movement, respiration, or heart activity. The patient gives birth to a 2296 g (5 lb 1 oz) male infant. Physical examination shows no signs of life. There are no visible malformations. The placenta is unremarkable. Which of the following is the most appropriate next step in management?",
    "answer": "To determine the most appropriate next step in management after a stillbirth, we first focus on identifying the underlying cause to guide future care for the mother and prevent recurrence. Here's the key reasoning:\n\n\n### Key Context Recap  \nThe case involves a 35-week stillbirth with no visible fetal malformations, no signs of life at birth, and a grossly unremarkable placenta. The primary goal post-delivery is to investigate the cause of fetal demise.\n\n\n### Critical Next Step  \nThe **most appropriate next step** is to perform a **fetal autopsy and detailed placental histopathological examination**.  \n\n#### Rationale:  \n1. **Fetal Autopsy**: Even with no visible malformations, an autopsy can detect hidden anatomical anomalies (e.g., cardiac defects), infections (e.g., sepsis), or metabolic disorders that were not apparent on gross exam.  \n2. **Placental Histopathology**: A grossly unremarkable placenta may have microscopic abnormalities (e.g., infarction, inflammation, vascular lesions) that indicate placental insufficiency, infection, or other causes of fetal compromise.  \n\nThese investigations are foundational to identifying the root cause of stillbirth and informing subsequent maternal workup (e.g., genetic testing, autoimmune screening) or future pregnancy planning.\n\n\n**Answer**: Perform a fetal autopsy and placental histopathological examination.  \n\n(Note: If this were a multiple-choice question, the correct option would align with this recommendation, such as \"Obtain fetal autopsy and placental histopathology.\")  \n\n\\boxed{Perform fetal autopsy and placental histopathological examination}",
    "expected_answer": "Recommend autopsy of the infant",
    "time": 37.701788902282715,
    "answer_length": 1620
  },
  {
    "question": "A 67-year-old man is hospitalized after several days of fever and increasing shortness of breath. Respiratory viral panel returns positive for influenza A and the patient is started on a standard five day course of oseltamivir. Despite therapy, his shortness of breath continues to worsen and his oxygen saturation decreases to the point where ICU transfer and intubation are required. Chest radiograph shows bilateral infiltrates. Clinical criteria are consistent with development of Acute Respiratory Distress Syndrome (ARDS). After several weeks of supportive therapy, the patient improves with lung function returning to near normal. Which of the following processes is involved in the regeneration of alveolar lining after damage to alveoli occurs?",
    "answer": "To address the question about alveolar lining regeneration after damage (e.g., in ARDS), we focus on the key cellular mechanisms involved:\n\n\n### Key Background  \nThe alveolar epithelium consists of two main cell types:  \n1. **Type I pneumocytes**: Thin, flattened cells responsible for gas exchange (cover ~95% of alveolar surface).  \n2. **Type II pneumocytes**: Cuboidal cells that secrete surfactant and act as **progenitor/stem cells** for the alveolar epithelium.  \n\n\n### Regeneration Process  \nWhen Type I cells are damaged (as in ARDS), **Type II pneumocytes proliferate** (divide to increase their numbers) and then **differentiate into Type I pneumocytes** to restore the intact alveolar lining. This process repairs the damaged gas-exchange barrier and allows lung function to recover.  \n\n\n### Conclusion  \nThe critical process involved in alveolar lining regeneration is the **proliferation of Type II alveolar epithelial cells followed by their differentiation into Type I alveolar epithelial cells**.\n\n\n**Answer**: Proliferation and differentiation of Type II alveolar epithelial cells into Type I alveolar epithelial cells.  \n\n(Note: If options were provided, the correct choice would align with this mechanism—e.g., \"Proliferation of Type II alveolar cells and their differentiation into Type I cells\".)",
    "expected_answer": "Proliferation of surfactant-secreting cells",
    "time": 26.78297996520996,
    "answer_length": 1317
  }
]